2023

Desai, N.R., Navaneethan, S.D., Nicholas, S.B., Pantalone, K.M., Wanner, C., Hamacher, S., ...Wheeler, D.C. (2023). Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. Journal of Diabetes and its Complications, 37 (4), doi:10.1016/j.jdiacomp.2023.108411
Beernink, J.M., Persson, F., Jongs, N., Laverman, G.D., Chertow, G.M., McMurray, J.J.V., ...Sjöström, C.D. (2023). Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.. Diabetes Care, doi:10.2337/dc22-1514
Yi, T.W., Smyth, B., Di Tanna, G.L., Arnott, C., Cardoza, K., Kang, A., ...Charytan, D.M. (2023). Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.. Am J Kidney Dis, S0272-6386(23)00537. doi:10.1053/j.ajkd.2022.12.015
Mark, P.B., Carrero, J.J., Matsushita, K., Sang, Y., Ballew, S.H., Grams, M.E., ...Chalmers, J. (2023). Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.. European Heart Journal, doi:10.1093/eurheartj/ehac825
Johansen, K.L., Cobitz, A.R., Singh, A.K., Macdougall, I.C., Lopes, R.D., Obrador, G.T., ...Okoro, T. (2023). The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease.. Kidney international, S0085-2538(23)00143-6-. doi:10.1016/j.kint.2023.02.019

2022

Thomson, P.C., Mark, P.B., Robertson, M., White, C., Anker, S.D., Bhandari, S., ...McMurray, J. (2022). An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial. Kidney International Reports, doi:10.1016/j.ekir.2022.05.008
Ebert, T., Sattar, N., Greig, M., Lamina, C., Froissart, M., Eckardt, K.-.U., ...Wheeler, D.C. (2022). Association between Analogue Compared with Human Insulin and the Outcomes of Mortality, Hospitalization, MACE, and Hypoglycemia in Hemodialysis Patients with Type 2 Diabetes: The ARO Research Initiative.
Cleary, F., Kim, L., Prieto-Merino, D., Wheeler, D., Steenkamp, R., Fluck, R., ...Loud, F. (2022). Association between practice coding of chronic kidney disease (CKD) in primary care and subsequent hospitalisations and death: a cohort analysis using national audit data. BMJ open, 12 (10), doi:10.1136/bmjopen-2022-064513
Lalayiannis, A.D., Crabtree, N.J., Ferro, C.J., Wheeler, D.C., Duncan, N.D., Smith, C., ...Kaur, A. (2022). Bone Mineral Density and Vascular Calcification in Children and Young Adults With CKD 4 to 5 or on Dialysis. Kidney International Reports, doi:10.1016/j.ekir.2022.10.023
Heerspink, H.J.L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., ...Di Tanna, G.L. (2022). Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2021.05.005
Woo, V.C., Tsoukas, M., Tobe, S., Slee, A., Rapattoni, W., Ang, F., ...Wheeler, D.C. (2022). Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE.
Seufert, J., Woo, V., Tsoukas, M.A., Tobe, S.W., Slee, A., Rapattoni, W., ...Wheeler, D.C. (2022). Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: data from the CANVAS Program and CREDENCE.
Pollock, C., James, G., Carrero, J.J., Khezrian, M., Fishbane, S., Chen, H., ...Lainscak, M. (2022). COMPARING CHARACTERISTICS OF PATIENTS (PTS) WITH CKD AND HYPERKALEMIA (HK) WITH AND WITHOUT A DIAGNOSTIC (DX) CODE FOR HK: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT.
Jongs, N., Chertow, G.M., Greene, T., McMurray, J.J.V., Langkilde, A.M., Correa-Rotter, R., ...Stefánsson, B.V. (2022). Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.. Journal of the American Society of Nephrology, doi:10.1681/ASN.2022030306
McEwan, P., Darlington, O., Miller, R., McMurray, J.J.V., Wheeler, D.C., Heerspink, H.J.L., ...Garcia Sanchez, J.J. (2022). Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.03790322
Rossing, P., Inzucchi, S.E., Vart, P., Jongs, N., Docherty, K.F., Jhund, P.S., ...Ponikowski, P. (2022). Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(21)00295-3
Mathur, V.S., Bushinsky, D.A., Inker, L., Klaerner, G., Li, E., Parsell, D., ...Wesson, D.E. (2022). Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis.. Nephrology Dialysis Transplantation, gfac289. doi:10.1093/ndt/gfac289
Briguori, C., Mathew, R.O., Huang, Z., Mavromatis, K., Hickson, L.J., Lau, W.L., ...Claes, K.J. (2022). Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. Journal of the American Heart Association, 11 (6), doi:10.1161/JAHA.121.022003
Li, J.-.W., Arnott, C., Heerspink, H.J.L., MBiostat, Q.L., Cannon, C.P., Wheeler, D.C., ...Agarwal, R. (2022). Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, doi:10.1161/JAHA.121.025045
Waijer, S.W., Vart, P., Cherney, D.Z., Chertow, G.M., Jongs, N., Langkilde, A.M., ...Rossing, P. (2022). Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, doi:10.1007/s00125-022-05694-6
Lv, J., Wong, M.G., Hladunewich, M.A., Jha, V., Hooi, L.S., Monaghan, H., ...Reich, H.N. (2022). Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.. JAMA, 327 (19), 1888-1898. doi:10.1001/jama.2022.5368
McMurray, J.J., Wheeler, D.C., Stefansson, B., Jongs, N., Postmus, D., Correa-Rotter, R., ...Sjostrom, C.D. (2022). Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure (vol 9, 807, 2022). JACC-HEART FAILURE, 10 (6), 446-447. doi:10.1016/j.jchf.2022.04.001
Heerspink, H.J.L., Chertow, G.M., Jongs, N., Correa-Rotter, R., Rossing, P., Sjostrom, C.D., ...Wheeler, D.C. (2022). Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.07290622
Schechter, M., Jongs, N., Chertow, G.M., Mosenzon, O., McMurray, J.J.V., Correa-Rotter, R., ...Toto, R.D. (2022). Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. Annals of Internal Medicine, doi:10.7326/M22-2115
Vart, P., Correa-Rotter, R., Hou, F.F., Jongs, N., Chertow, G.M., Langkilde, A.M., ...Stefansson, B.V. (2022). Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney International Reports, 7 (4), 699-707. doi:10.1016/j.ekir.2022.01.1060
Singh, A.K., Cizman, B., Carroll, K., McMurray, J.J., Perkovic, V., Jha, V., ...Obrador, G.T. (2022). Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial. JAMA Internal Medicine, doi:10.1001/jamainternmed.2022.0605
Persson, F., Rossing, P., Jongs, N., Chertow, G.M., Hou, F.F., Vart, P., ...Toto, R.D. (2022). Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study.
Agarwal, R., Hauske, S.J., Wheeler, D.C., Doi, K., Elsaesser, A., Ritter, I., ...Wanner, C. (2022). Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in >15 000 individuals.. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, doi:10.1111/dom.14694
Vart, P., Vaduganathan, M., Jongs, N., Remuzzi, G., Wheeler, D.C., Hou, F.F., ...Heerspink, H.J.L. (2022). Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.08900722
Heerspink, H., James, G., Nolan, S., Carrero, J.J., Arnold, M., Pecoits-Filho, R., ...Kanda, E. (2022). EVALUATING CLINICAL OUTCOMES IN PATIENTS (PTS) WITH CKD WITH RAPID AND NON-RAPID EGFR DECLINE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT.
McEwan, P., Boyce, R., Sanchez, J.J.G., Sjöström, C.D., Stefansson, B., Nolan, S., ...McMurray, J.J.V. (2022). Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfac280
Hailu Habte-Asres, H., Murrells, T., Nitsch, D., Wheeler, D.C., Forbes, A. (2022). Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study. Diabetes Research and Clinical Practice, 193 doi:10.1016/j.diabres.2022.110117
Pollock, C., James, G., Garcia Sanchez, J.J., Carrero, J.J., Arnold, M., Lam, C.S.P., ...Wheeler, D.C. (2022). Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clinical Kidney Journal, doi:10.1093/ckj/sfac168
Staplin, N., Haynes, R., Mayne, K.J., Roddick, A.J., Neuen, B.L., Hauske, S.J., ...Cherney, D.Z. (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. LANCET, 400 (10365), 1788-1801. doi:10.1016/S0140-6736(22)02074-8
Singh, A., Sackeyfio, A., Lopes, R.D., Kovesdy, C.P., Dasgupta, I., Wheeler, D.C., ...Ballew, N. (2022). INDIRECT TREATMENT COMPARISON BETWEEN DAPRODUSTAT AND ROXADUSTAT IN NON-DIALYSIS PATIENTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE: AN ANALYSIS OF ENERGY/FATIGUE AS MEASURED BY THE SF-36 VITALITY SCORE.
James, G., Garcia Sanchez, J.J., Carrero, J.J., Kumar, S., Pecoits-Filho, R., Heerspink, H.J.L., ...Kanda, E. (2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney International Reports, doi:10.1016/j.ekir.2022.05.033
Forst, T., Mathieu, C., Giorgino, F., Wheeler, D.C., Papanas, N., Schmieder, R.E., ...Tuttle, K.R. (2022). New strategies to improve clinical outcomes for diabetic kidney disease. BMC Medicine, 20 (1), doi:10.1186/s12916-022-02539-2
Chertow, G.M., Vart, P., Jongs, N., Langkilde, A.M., McMurray, J.J.V., Correa-Rotter, R., ...Toto, R.D. (2022). Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD.. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, doi:10.1111/dom.14641
Bottomley, M.J., Beckwith, H., McMahon, A., Nation, M., Wheeler, D.C., Greenwood, S., ...Sheerin, N.S. (2022). Research engagement by British early-career practitioners in nephrology: a multidisciplinary survey. BMJ Open, 12 (12), doi:10.1136/bmjopen-2022-066212
Young, T.K., Toussaint, N.D., Di Tanna, G.L., Arnott, C., Hockham, C., Kang, A., ...Agarwal, R. (2022). Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. Journal of Diabetes Research, 2022 doi:10.1155/2022/9998891
Tuttle, K.R., Levin, A., Nangaku, M., Kadowaki, T., Agarwal, R., Hauske, S.J., ...Wanner, C. (2022). Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.. Diabetes Care, doi:10.2337/dc21-2034
Neuen, B.L., Oshima, M., Agarwal, R., Arnott, C., Cherney, D.Z., Edwards, R., ...Neal, B. (2022). Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. Circulation, doi:10.1161/CIRCULATIONAHA.121.057736
Feher, M., Hinton, W., Forbes, A., Munro, N., Joy, M., Wheeler, D., de Lusignan, S. (2022). Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study). JMIR Research Protocols, 11 (7), doi:10.2196/34206
Lalayiannis, A.D., Ferro, C.J., Wheeler, D.C., Duncan, N.D., Smith, C., Popoola, J., ...Sinha, M.D. (2022). The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis. Clinical Kidney Journal, 15 (2), 287-294. doi:10.1093/ckj/sfab168
Greenwood, S.A., Beckley-Hoelscher, N., Asgari, E., Ayis, S., Baker, L.A., Banerjee, D., ...Burton, J. (2022). The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial. BMC Nephrology, 23 (1), doi:10.1186/s12882-022-02896-3
Caskey, F.J., Procter, S., MacNeill, S.J., Wade, J., Taylor, J., Rooshenas, L., ...Davenport, A. (2022). The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes. Trials, 23 doi:10.1186/s13063-022-06357-y
Liao, J., Kang, A., Xia, C., Young, T., Tanna, G.L.D., Arnott, C., ...Bakris, G. (2022). The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.. Diabetes and Metabolism, 101331. doi:10.1016/j.diabet.2022.101331
Provenzano, M., Jongs, N., Vart, P., Stefánsson, B.V., Chertow, G.M., Langkilde, A.M., ...Sjöström, C.D. (2022). The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Kidney International Reports, 7 (3), 436-443. doi:10.1016/j.ekir.2021.12.013
Wilding, J.P.H., Evans, M., Fernando, K., Gorriz, J.L., Cebrian, A., Diggle, J., ...Ali, A. (2022). The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, doi:10.1007/s13300-022-01228-w

2021

Yi, T.W., Smyth, B., Kang, A., Cardoza, K., Di Tanna, G.L., Arnott, C., ...Cannon, C.P. (2021). 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial.
Rossing, P., Vart, P., Chertow, G.M., Hou, F.F., Jongs, N., Mcmurray, J.J., ...Langkilde, A.M. (2021). 130-LB: Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease.
Liao, J., Kang, A., Xia, C., Arnott, C., Di Tanna, G.L., Krishnan, A.V., ...Heerspink, H.L. (2021). 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial.
Cardoza, K., Kang, A., Smyth, B., Yi, T.W., Di Tanna, G.L., Pollock, C.A., ...Zinman, B. (2021). 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE.
Persson, F., Rossing, P., Vart, P., Chertow, G.M., Hou, F.F., McMurray, J.J., ...Toto, R.D. (2021). 317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial.
Wheeler, D.C., Toto, R.D., Stefansson, B.V., Jongs, N., Chertow, G.M., Greene, T., ...Correa-Rotter, R. (2021). A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.. Kidney International, doi:10.1016/j.kint.2021.03.033
Heerspink, H.J., Cherney, D., Postmus, D., Stefánsson, B.V., Chertow, G.M., Dwyer, J.P., ...McMurray, J.J. (2021). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.. Kidney International, doi:10.1016/j.kint.2021.09.005
Ye, N., Jardine, M.J., Oshima, M., Hockham, C., Heerspink, H.J.L., Agarwal, R., ...Chang, T.I. (2021). Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.. Circulation, doi:10.1161/CIRCULATIONAHA.120.048740
Wittbrodt, E., Carrero, J.J., James, G., Fishbane, S., Kumar, S., Pecoits-Filho, R., ...Hedman, K. (2021). BURDEN OF ANEMIA IN PATIENTS WITH AND WITHOUT DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE: A REPORT FROM THE RETROSPECTIVE COHORT FROM DISCOVER CKD.
Wittbrodt, E., Carrero, J.J., James, G., Fishbane, S., Kumar, S., Pecoits-Filho, R., ...Hedman, K. (2021). CHARACTERISTICS OF PATIENTS WITH AND WITHOUT DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE AND ANEMIA RECEIVING BLOOD TRANSFUSIONS AND INTRAVENOUS IRON: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT.
Wheeler, D.C. (2021). Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?. NEW ENGLAND JOURNAL OF MEDICINE, 385 (27), 2574-2575. doi:10.1056/NEJMe2118149
Jong, N., Chertow, G., Hou, F.F., McMurray, J., Correa-Rotter, R., Rossing, P., ...Langkilde, A.M. (2021). DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL.
Heerspink, H.J.L., Langkilde, A.-.M., Wheeler, D.C. (2021). Dapagliflozin in Patients with Chronic Kidney Disease.. N Engl J Med, 384 (4), 389-390. doi:10.1056/NEJMc2032809
Singh, A.K., Carroll, K., McMurray, J.J., Solomon, S., Jha, V., Johansen, K.L., ...Waikar, S.S. (2021). Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. NEW ENGLAND JOURNAL OF MEDICINE, doi:10.1056/NEJMoa2113380
Singh, A.K., Carroll, K., Perkovic, V., Solomon, S., Jha, V., Johansen, K.L., ...Waikar, S.S. (2021). Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. NEW ENGLAND JOURNAL OF MEDICINE, doi:10.1056/NEJMoa2113379
Stefánsson, B.V., Heerspink, H.J.L., Wheeler, D.C., Sjöström, C.D., Greasley, P.J., Sartipy, P., ...Correa-Rotter, R. (2021). Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline. Data Brief, 37 doi:10.1016/j.dib.2021.107237
McMurray, J.J.V., Wheeler, D.C., Stefánsson, B.V., Jongs, N., Postmus, D., Correa-Rotter, R., ...Hou, F.F. (2021). Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, doi:10.1161/CIRCULATIONAHA.120.051675
Heerspink, H.J.L., Jongs, N., Chertow, G.M., Langkilde, A.M., McMurray, J.J.V., Correa-Rotter, R., ...Toto, R.D. (2021). Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(21)00242-4
Jongs, N., Greene, T., Chertow, G.M., McMurray, J.J.V., Langkilde, A.M., Correa-Rotter, R., ...Toto, R.D. (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(21)00243-6
Sarraju, A., Li, J., Cannon, C.P., Chang, T.I., Agarwal, R., Bakris, G., ...Heerspink, H.J.L. (2021). Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, doi:10.1016/j.ahj.2020.12.008
Neuen, B.L., Oshima, M., Perkovic, V., Arnott, C., Bakris, G., Cannon, C.P., ...Neal, B. (2021). Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial.
Wheeler, D.C., Weir, M.R., Gogate, J., Perkovic, V., Mahaffey, K.W. (2021). Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial.
Wheeler, D.C., Weir, M., Gogate, J., Perkovic, V., Mahaffey, K.W. (2021). EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL.
Neuen, B.L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., ...Górriz, J.L. (2021). Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.. European Heart Journal, doi:10.1093/eurheartj/ehab497
McMurray, J.J.V., Wheeler, D.C., Stefánsson, B.V., Jongs, N., Postmus, D., Correa-Rotter, R., ...Sjöström, C.D. (2021). Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC: Heart Failure, doi:10.1016/j.jchf.2021.06.017
Chertow, G.M., Vart, P., Jongs, N., Toto, R.D., Gorriz, J.L., Hou, F.F., ...Sjöström, C.D. (2021). Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.. Journal of the American Society of Nephrology, 32 (9), 2352-2361. doi:10.1681/ASN.2021020167
Wheeler, D.C., Stefánsson, B.V., Jongs, N., Chertow, G.M., Greene, T., Hou, F.F., ...Toto, R.D. (2021). Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.. Lancet Diabetes Endocrinol, 9 (1), 22-31. doi:10.1016/S2213-8587(20)30369-7
Heerspink, H.J.L., Sjöström, C.D., Jongs, N., Chertow, G.M., Kosiborod, M., Hou, F.F., ...Kurlyandskaya, R. (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.. Eur Heart J, 42 (13), 1216-1227. doi:10.1093/eurheartj/ehab094
Edwards, N.C., Price, A.M., Mehta, S., Hiemstra, T.F., Kaur, A., Greasley, P.J., ...Farrah, T. (2021). Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.. Clinical Journal of the American Society of Nephrology, 16 (10), 1491-1501. doi:10.2215/CJN.01930221
Persson, F., Rossing, P., Vart, P., Chertow, G.M., Hou, F.F., Jongs, N., ...Stefansson, B.V. (2021). Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care, doi:10.2337/dc21-0300
Persson, F., Rossing, P., Vart, P., Chertow, G.M., Hou, F.F., McMurray, J.J., ...Toto, R.D. (2021). Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial.
Dritsoula, A., Kislikova, M., Oomatia, A., Webster, A.P., Beck, S., Ponticos, M., ...Oates, T. (2021). Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology. Epigenetics, 1-11. doi:10.1080/15592294.2020.1819666
Ramesh, S., James, M.T., Holroyd-Leduc, J.M., Wilton, S.B., Seely, E.W., Hemmelgarn, B.R., ...Ahmed, S.B. (2021). Estradiol and mortality in women with end-stage kidney disease. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa126
Greenwood, S.A., Koufaki, P., Macdonald, J.H., Bulley, C., Bhandari, S., Burton, J.O., ...Kalra, P.A. (2021). Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. Health Technol Assess, 25 (40), 1-52. doi:10.3310/hta25400
Jhund, P.S., Petrie, M.C., Robertson, M., Mark, P.B., MacDonald, M.R., Connolly, E., ...Kalra, P.A. (2021). Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC: Heart Failure, doi:10.1016/j.jchf.2021.04.005
Petrie, M.C., Jhund, P.S., Connolly, E., Mark, P.B., MacDonald, M.R., Robertson, M., ...Kalra, P.A. (2021). High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis.. Cardiovascular Research, doi:10.1093/cvr/cvab317
Jardine, M., Zhou, Z., Lambers Heerspink, H.J., Hockham, C., Li, Q., Agarwal, R., ...Greene, T. (2021). Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.15260920
Pecoits-Filho, R., James, G., Carrero, J.J., Wittbrodt, E., Fishbane, S., Sultan, A.A., ...Chen, H.T. (2021). Methods and rationale of the DISCOVER CKD global observational study. Clinical Kidney Journal, 14 (6), 1570-1578. doi:10.1093/ckj/sfab046
Evangelidis, N., Sautenet, B., Manera, K.E., Howell, M., Craig, J.C., Viecelli, A.K., ...Cho, Y. (2021). Perspectives on blood pressure by patients on haemo- and peritoneal dialysis.. Nephrology (Carlton), doi:10.1111/nep.13775
Greenwood, S.A., Koufaki, P., Macdonald, J.H., Bhandari, S., Burton, J.O., Dasgupta, I., ...Kean, S. (2021). Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney International Reports, doi:10.1016/j.ekir.2021.05.034
Neuen, B.L., Ohkuma, T., Neal, B., Matthews, D.R., de Zeeuw, D., Mahaffey, K.W., ...Jardine, M.J. (2021). Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2020.06.018
Lalayiannis, A.D., Crabtree, N.J., Ferro, C.J., Askiti, V., Mitsioni, A., Biassoni, L., ...Duncan, N.D. (2021). Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa199
Wheeler, D.C., Jongs, N., Stefansson, B.V., Chertow, G.M., Greene, T., Hou, F.F., ...Nowicki, M. (2021). Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial.. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfab335
Evangelidis, N., Sautenet, B., Madero, M., Tong, A., Ashuntantang, G., Sanabria, L.C., ...Levey, A.S. (2021). Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials, 22 (1), doi:10.1186/s13063-021-05574-1
Mark, P.B., Jhund, P.S., Walters, M.R., Petrie, M.C., Power, A., White, C., ...Bhandari, S. (2021). Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. Kidney360, 2 (11), 1761-1769. doi:10.34067/KID.0004272021
Lalayiannis, A.D., Ferro, C.J., Wheeler, D.C., Duncan, N.D., Smith, C., Popoola, J., ...Sinha, M.D. (2021). STRUCTURAL AND FUNCTIONAL CARDIOVASCULAR DISEASE IN CHILDREN AND YOUNG ADULTS WITH CKD AND ON DIALYSIS.
Singh, A.K., Blackorby, A., Cizman, B., Carroll, K., Cobitz, A.R., Davies, R., ...Kler, L. (2021). Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.. Nephrol Dial Transplant, doi:10.1093/ndt/gfab065
Fotheringham, J., Latimer, N., Froissart, M., Kronenberg, F., Stenvinkel, P., Floege, J., ...Wheeler, D.C. (2021). Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study.. Clin Kidney J, 14 (2), 665-672. doi:10.1093/ckj/sfaa250
Perkovic, V., Blackorby, A., Cizman, B., Carroll, K., Cobitz, A.R., Davies, R., ...Lopes, R.D. (2021). The ASCEND-ND trial: Study design and participant characteristics.. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfab318
Chertow, G., Vart, P., Jongs, N., Toto, R., Gorriz, J.L., Hou, F.F., ...Sjostrom, C.D. (2021). THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR < 30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIAL.
Heerspink, J.L., Wheeler, D.C., Vart, P., Jongs, N., Hou, F.F., Langkilde, A.M., ...Toto, R.D. (2021). The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure.
Evans, R.D.R., Smyth, B., Levin, A., Jha, V., Wheeler, D.C., Jardine, M., ...de Zeeuw, D. (2021). The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals.. Kidney Int, doi:10.1016/j.kint.2020.10.048
Bjornstad, P., Greasley, P.J., Wheeler, D.C., Chertow, G.M., Langkilde, A.M., Heerspink, H.J.L., van Raalte, D.H. (2021). The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure.. Journal of Cardiac Failure, doi:10.1016/j.cardfail.2021.07.003
Greenwood, S.A., Koufaki, P., Macdonald, J., Bhandari, S., Burton, J., Dasgupta, I., ...Kean, S. (2021). The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial.. CKJ: Clinical Kidney Journal, 14 (5), 1345-1355. doi:10.1093/ckj/sfaa107
McEwan, P., Darlington, O., Boyce, R., Heerspink, H.L., Wheeler, D.C., Sanchez, J.J.G. (2021). THE SOCIETAL IMPACT OF DELAYED DIALYSIS INITIATION ASSOCIATED WITH DAPAGLIFLOZIN BASED ON THE RESULTS OF DAPA-CKD.
Wong, M.G., Lv, J., Hladunewich, M.A., Jha, V., Hooi, L.S., Monaghan, H., ...Cattran, D. (2021). The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 1-10. doi:10.1159/000519812
Ebert, T., Qureshi, A.R., Lamina, C., Fotheringham, J., Froissart, M., Eckardt, K.U., ...Stenvinkel, P. (2021). Time-dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition. Journal of Internal Medicine, doi:10.1111/joim.13291
Ishida, J.H., Chauhan, C., Gillespie, B., Gruchalla, K., McCullough, P.A., Quella, S., ...Malley, M.A. (2021). Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease.. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.17561120

2020

Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., ...Hansen, T.B. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.. European Heart Journal, doi:10.1093/eurheartj/ehz486
Oshima, M., Jardine, M.J., Agarwal, R., Bakris, G., Cannon, C., Charytan, D.M., ...Levin, A. (2020). Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE.
Heerspink, H.J.L., Oshima, M., Jardine, M.J., Agarwal, R., Bakris, G., Charytan, D.M., ...Neal, B. (2020). Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE.
Sarraju, A., Li, J., Cannon, C.P., Chang, T.I., Agarwal, R., Bakris, G.L., ...Heerspink, H.J.L. (2020). CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS.
Stefánsson, B.V., Heerspink, H.J.L., Wheeler, D.C., Sjöström, C.D., Greasley, P.J., Sartipy, P., ...Correa-Rotter, R. (2020). Correction of anemia by dapagliflozin in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 107729. doi:10.1016/j.jdiacomp.2020.107729
McMurray, J.J., Wheeler, D.C., Stefansson, B.V., Rotter, R.C., Chertow, G.M., Greene, T., ...Sjostrom, D. (2020). Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD).
McMurray, J.J., Wheeler, D.C., Stefansson, B.V., Rotter, R.C., Chertow, G.M., Greene, T., ...Sjostrom, D. (2020). Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD).
McMurray, J.J.V., Wheeler, D.C., Stefansson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., ...Sjostrom, C.D. (2020). Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD).
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.-.F., ...Rossing, P. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, doi:10.1056/NEJMoa2024816
Chan, C.T., Blankestijn, P.J., Dember, L.M., Gallieni, M., Harris, D.C.H., Lok, C.E., ...Cheung, M. (2020). Dialysis initiation, modality choice, access, and prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Nephrology and Dialysis, 22 (2), 152-167. doi:10.28996/2618-9801-2020-2-152-167
Oshima, M., Neuen, B.L., Li, J., Perkovic, V., Charytan, D.M., de Zeeuw, D., ...Mahaffey, K.W. (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.. J Am Soc Nephrol, doi:10.1681/ASN.2020050723
Li, J., Jardine, M.J., Neal, B., Heerspink, H.L., Cannon, C., Agarwal, R., ...Edwards, R. (2020). Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Bakris, G., Oshima, M., Mahaffey, K.W., Agarwal, R., Cannon, C.P., Capuano, G., ...Greene, T. (2020). Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m²: Subgroup Analysis of the Randomized CREDENCE Trial. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.10140620
Oshima, M., Neuen, B.L., Jardine, M.J., Bakris, G., Edwards, R., Levin, A., ...Rosenthal, N. (2020). Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.. Lancet Diabetes Endocrinol, 8 (11), 903-914. doi:10.1016/S2213-8587(20)30300-4
Neuen, B., Mahaffey, K., Cannon, C.P., Jardine, M., Heerspink, H.L., Neal, B., ...Agarwal, R. (2020). EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL.
Levin, A., Perkovic, V., Wheeler, D.C., Hantel, S., George, J.T., von Eynatten, M., ...EMPA-REG OUTCOME, I.n.v.e.s.t.i.g.a.t.o.r.s. (2020). Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.. Clin J Am Soc Nephrol, doi:10.2215/CJN.14901219
O'Lone, E., Viecelli, A.K., Craig, J.C., Tong, A., Sautenet, B., Herrington, W.G., ...Krane, V. (2020). Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop.. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2020.01.022
Cannon, C.P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D.M., ...Heerspink, H.J.L. (2020). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. Circulation, doi:10.1161/CIRCULATIONAHA.119.044359
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., ...Hansen, T.B. (2020). Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). REVISTA ESPANOLA DE CARDIOLOGIA, 73 (5), doi:10.1016/j.recesp.2019.11.024
Mccafferty, K., Caplin, B., Knight, S., Hockings, P., Wheeler, D., Fan, S.L., ...Papastefanou, V. (2020). HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol.. BMJ Open, 10 (9), e033923. doi:10.1136/bmjopen-2019-033923
Fotheringham, J., Smith, M.T., Froissart, M., Kronenberg, F., Stenvinkel, P., Floege, J., ...Wheeler, D.C. (2020). Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study.. BMC Nephrol, 21 (1), 218. doi:10.1186/s12882-020-01874-x
O'Lone, E., Howell, M., Viecelli, A.K., Craig, J.C., Tong, A., Sautenet, B., ...Jardine, M. (2020). Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals.. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa008
Oshima, M., Jardine, M.J., Agarwal, R., Bakris, G., Cannon, C.P., Charytan, D.M., ...Levin, A. (2020). Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.. Kidney Int, doi:10.1016/j.kint.2020.10.042
Levin, A., Agarwal, R., Herrington, W.G., Heerspink, H.L., Mann, J.F.E., Shahinfar, S., ...Nangaku, M. (2020). International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 98 (4), 849-859. doi:10.1016/j.kint.2020.07.013
Macdougall, I.C., Bhandari, S., White, C., Anker, S.D., Farrington, K., Kalra, P.A., ...Robertson, M. (2020). Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. J Am Soc Nephrol, doi:10.1681/ASN.2019090972
Małyszko, J., Bamias, A., Danesh, F.R., Dębska-Ślizień, A., Gallieni, M., Gertz, M.A., ...Cheung, M. (2020). KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation.. Kidney Int, 98 (6), 1407-1418. doi:10.1016/j.kint.2020.07.012
Porta, C., Bamias, A., Danesh, F.R., Dębska-Ślizień, A., Gallieni, M., Gertz, M.A., ...Cheung, M. (2020). KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney International, 98 (5), 1108-1119. doi:10.1016/j.kint.2020.06.046
Li, J., Neal, B., Heerspink, H.L., Arnott, C., Cannon, C., Agarwal, R., ...Greene, T. (2020). Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD).
Tong, A., Levey, A.S., Eckardt, K.-.U., Anumudu, S., Arce, C.M., Baumgart, A., ...Lightstone, L. (2020). Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health.. Clin J Am Soc Nephrol, 15 (7), 937-948. doi:10.2215/CJN.00900120
Gonzalez, A.M., Gutman, T., Lopez-Vargas, P., Anumudu, S., Arce, C.M., Craig, J.C., ...Levey, A.S. (2020). Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2020.03.022
Heerspink, H.J.L., Stefansson, B.V., Chertow, G.M., Correa-Rotter, R., Greene, T., Hou, F.-.F., ...Toto, R. (2020). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant, 35 (2), 274-282. doi:10.1093/ndt/gfz290
Rossignol, P., Ruilope, L.M., Cupisti, A., Ketteler, M., Wheeler, D.C., Pignot, M., ...Lund, L.H. (2020). Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review.. Clin Kidney J, 13 (4), 714-719. doi:10.1093/ckj/sfz129
Jardine, M.J., Zhou, Z., Mahaffey, K.W., Oshima, M., Agarwal, R., Bakris, G., ...Charytan, D.M. (2020). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.. J Am Soc Nephrol, 31 (5), 1128-1139. doi:10.1681/ASN.2019111168
Wheeler, D.C., James, J., Patel, D., Viljoen, A., Ali, A., Evans, M., ...Newland-Jones, P. (2020). SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.. Diabetes Ther, doi:10.1007/s13300-020-00930-x
Shivakumar, O., Sattar, N., Wheeler, D.C. (2020). Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease.. Nephrol Dial Transplant, 35 (Supplement_1), i43-i47. doi:10.1093/ndt/gfz292
Wheeler, D.C., Stefansson, B.V., Batiushin, M., Bilchenko, O., Cherney, D.Z.I., Chertow, G.M., ...Pecoits-Filho, R. (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.. Nephrol Dial Transplant, doi:10.1093/ndt/gfaa234

2019

Wang, A.Y.-.M., Akizawa, T., Bavanandan, S., Hamano, T., Liew, A., Lu, K.-.C., ...Fung, S.K.-.S. (2019). 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. KIDNEY INTERNATIONAL REPORTS, 4 (11), 1523-1537. doi:10.1016/j.ekir.2019.09.007
Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C.D., Wheeler, D.C., ...Heerspink, H.J.L. (2019). Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(19)30086-5
Lamina, C., Kronenberg, F., Stenvinkel, P., Froissart, M., Forer, L., Schönherr, S., ...Floege, J. (2019). Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.. Nephrol Dial Transplant, doi:10.1093/ndt/gfz060
Ha, J.T., Neuen, B.L., Cheng, L.P., Jun, M., Toyama, T., Gallagher, M.P., ...Palmer, S.C. (2019). Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Annals of Internal Medicine,
Cheung, A., Chang, T., Cushman, W., Furth, S., Ix, J.H., Pecoits-Filho, R., ...Tomson, C. (2019). Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2018.12.025
Mahaffey, K.W., Jardine, M., Bompoint, S., Cannon, C., Bruce, N., Herspink, L.H.J., ...Capuano, G. (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial. Circulation, doi:10.1161/CIRCULATIONAHA.119.042007
Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., ...Bull, S. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.. New England Journal of Medicine, doi:10.1056/NEJMoa1811744
Sarnak, M.J., Amann, K., Bangalore, S., Cavalcante, J.L., Charytan, D.M., Craig, J.C., ...Landmesser, U. (2019). Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 74 (14), 1823-1838. doi:10.1016/j.jacc.2019.08.1017
Marwick, T.H., Amann, K., Bangalore, S., Cavalcante, J.L., Charytan, D.M., Craig, J.C., ...Landmesser, U. (2019). Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 96 (4), 836-849. doi:10.1016/j.kint.2019.06.025
Louie, K.S., Erhard, C., Wheeler, D.C., Stenvinkel, P., Fouqueray, B., Floege, J. (2019). Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.. J Nephrol, doi:10.1007/s40620-019-00686-z
Macdougall, I.C., White, C., Anker, S.D., Bhandari, S., Farrington, K., Kalra, P.A., ...Wheeler, D.C. (2019). Correction: Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. The New England Journal of Medicine, 380 (5), 502. doi:10.1056/NEJMx180044
Schlackow, I., Kent, S., Herrington, W., Emberson, J., Haynes, R., Reith, C., ...Baigent, C. (2019). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 96 (1), 170-179. doi:10.1016/j.kint.2019.01.028
Chan, C.T., Blankestijn, P.J., Dember, L.M., Gallieni, M., Harris, D., Lok, C.E., ...Cheung, M. (2019). Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2019.01.017
Viecelli, A.K., Polkinghorne, K.R., Pascoe, E.M., Paul-Brent, P.-.A., Hawley, C.M., Badve, S.V., ...Mori, T.A. (2019). Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 14 (3), doi:10.1371/journal.pone.0213274
House, A.A., Wanner, C., Sarnak, M.J., Piña, I.L., McIntyre, C.W., Komenda, P., ...Cleland, J.G.F. (2019). Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2019.02.022
Cherney, D.Z.I., Repetto, E., Wheeler, D.C., Arnold, S.V., MacLachlan, S., Hunt, P.R., ...Kosiborod, M. (2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. American Journal of Nephrology, 1-9. doi:10.1159/000504558
Macdougall, I.C., White, C., Reid, C., Anker, S.D., Bhandari, S., Farrington, K., ...Tomson, C. (2019). IV IRON DOSING AND INFECTION RISK IN THE PIVOTAL TRIAL: A PRE-SPECIFIED SECONDARY ANALYSIS.
Floege, J., Barbour, S., Cattran, D.C., Hogan, J.J., Nachman, P.H., Tang, S.C.W., ...Winkelmayer, W.C. (2019). Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2018.10.018
Rovin, B.H., Caster, D.J., Cattran, D.C., Gibson, K.L., Hogan, J.J., Moeller, M.J., ...Winkelmayer, W.C. (2019). Management and Treatment of Glomerular Diseases (Part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2018.11.008
Muskiet, M., Wheeler, D.C., Heerspink, H. (2019). New pharmacological strategies for protecting kidney function in type 2 diabetes. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(18)30263-8
Muskiet, M.H.A., Wheeler, D.C., Heerspink, H.J.L. (2019). New pharmacological strategies for protecting kidney function in type 2 diabetes (vol 7, pg 397, 2018). LANCET DIABETES & ENDOCRINOLOGY, 7 (5), E5. doi:10.1016/S2213-8587(19)30035-X
Clase, C.M., Carrero, J.-.J., Ellison, D.H., Grams, M.E., Hemmelgarn, B.R., Jardine, M.J., ...Obrador, G.T. (2019). Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2019.09.018
Idzerda, N.M.A., Stefansson, B.V., Pena, M.J., Sjostrom, D.C., Wheeler, D.C., Heerspink, H.J.L. (2019). Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.. Nephrol Dial Transplant, doi:10.1093/ndt/gfz064
Inker, L.A., Grams, M.E., Levey, A.S., Coresh, J., Cirillo, M., Collins, J.F., ...Heine, G.H. (2019). Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. AMERICAN JOURNAL OF KIDNEY DISEASES, 73 (2), 206-217. doi:10.1053/j.ajkd.2018.08.013
Lange Neuen, B., Young, T., Heerspink, H., Neal, B., Perkovic, V., Billot, L., ...Arnott, C. (2019). SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes and Endocrinology, doi:10.1016/S2213-8587(19)30256-6

2018

Cherney, D.Z.I., Wheeler, D.C., Kosiborod, M., Arnold, S.V., MacLachlan, S., Hunt, P.R., ...Vora, J. (2018). Cardiovascular outcomes and mortality in type 2 diabetes with associated cardio-renal-metabolic comorbidities.
O'Lone, E., Viecelli, A.K., Craig, J.C., Tong, A., Sautenet, B., Roy, D., ...Jardine, M. (2018). Cardiovascular Outcomes Reported in Hemodialysis Trials. Journal of the American College of Cardiology, 71 (24), 2802-2810. doi:10.1016/j.jacc.2018.04.012
Turakhia, M.P., Blankestijn, P.J., Carrero, J.J., Clase, C., Deo, R., Herzog, C.A., ...Reinecke, H. (2018). Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal, doi:10.1093/eurheartj/ehy060
Tong, A., Crowe, S., Gill, J.S., Harris, T., Hemmelgarn, B., Manns, B., ...Wheeler, D.C. (2018). Clinicians’ and researchers’ perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. BMJ Open, doi:10.1136/bmjopen-2017-021198
Verberne, W.R., Das-Gupta, Z., Allegretti, A.S., Bart, H.A.J., van Biesen, W., García-García, G., ...Jager, K.J. (2018). Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2018.10.007
Wheeler, D.C., Haynes, R., Judge, P.K., Staplin, N., Herrington, W.G., Storey, B.C., ...Cockwell, P. (2018). Effects of Sacubitril/Valsartan versus Irbesartan in patients with chronic kidney disease: a randomised double-blind trial.. Circulation, doi:10.1161/CIRCULATIONAHA.118.034818
Dekkers, C.C.J., Wheeler, D.C., Sjostrom, C.D., Stefansson, B.V., Cain, V., Heerspink, H.J.L. (2018). Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfx350
Marthi, A., Donovan, K., Haynes, R., Wheeler, D.C., Baignent, C., Rooney, C.M., ...Holland, L. (2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology, doi:10.1681/ASN.2017121334
Wheeler, D.C., Kim, L.G., Cleary, F., Caplin, B., Nitsch, D., Hull, S.A. (2018). How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfx280
Tong, A., Manns, B., Wang, A.Y.M., Hemmelgarn, B., Wheeler, D.C., Gill, J., ...Harris, T. (2018). Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney International, doi:10.1016/j.kint.2018.08.018
Eckardt, K.-.U., Bansal, N., Coresh, J., Evans, M., Grams, M.E., Herzog, C.A., ...Stevens, P.E. (2018). Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.. Kidney international, doi:10.1016/j.kint.2018.02.006
Macdougall, I.C., White, C., Anker, S.D., Bhandari, S., Farrington, K., Kalra, P.A., ...Wheeler, D. (2018). Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. The New England Journal of Medicine, doi:10.1056/NEJMoa1810742
Wheeler, D.C., Winkelmayer, W.C. (2018). KDIGO 2018 CLINICAL PRACTICE GUIDELINE FOR THE PREVENTION, DIAGNOSIS, EVALUATION, AND TREATMENT OF HEPATITIS C IN CHRONIC KIDNEY DISEASE. KIDNEY INTERNATIONAL SUPPLEMENTS, 8 (3), 91-165. doi:10.1016/j.kisu.2018.06.001
Wheeler, D.C., Swanepoel, C.R., Atta, M.G., D'Agati, V.D., Estrella, M.M., Fogo, A.B., ...Winkler, C.A. (2018). Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2017.11.007
Buti, J., Koukos, G., Caplin, B., Wheeler, D., D'Aiuto, F. (2018). Poor Oral Health and Kidney Disease Progression. Five-years Longitudinal Study.
Macdougall, I.C., White, C., Anker, S.D., Bhandari, S., Farrington, K., Kalra, P.A., ...Tomson, C.R.V. (2018). Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. American Journal of Nephrology, doi:10.1159/000493551
Evans, M., Grams, M.E., Sang, Y., Astor, B.C., Blankestijn, P.J., Brunskill, N.J., ...Levin, A. (2018). Risk Factors for Prognosis in Patients With Severely Decreased GFR. Kidney International Reports, doi:10.1016/j.ekir.2018.01.002
Sautenet, B., Tong, A., Williams, G., Hemmelgarn, B.R., Manns, B., Wheeler, D.C., ...Crowe, S. (2018). Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2017.11.010
Wheeler, D.C., Kovesdy, C., Matsushita, K., Sang, Y., Brunskill, N.J., Carrero, J.J., ...Kirayama, A. (2018). Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. European Heart Journal, doi:10.1093/eurheartj/ehy100
Jardine, M.J., Mahaffey, K.W., Neal, B., Agarwal, R., Bakris, G., Brenner, B.M., ...de Zeeuw, D. (2018). The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, doi:10.1159/000484633
Hull, S.A., Nitsch, D., Griffith, K., Wheeler, D.C., Caplin, B.D. (2018). The National CKD Audit: a primary care condition that deserves more attention. British Journal of General Practice, doi:10.3399/bjgp18X697997

2017

Hayer, M.K., Edwards, N.C., Slinn, G., Moody, W.E., Steeds, R.P., Ferro, C.J., ...Webster, R. (2017). A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. American Heart Journal, 191 37-46. doi:10.1016/j.ahj.2017.05.008
Caplin, B.D., Kim, L., Cleary, F., Hull, S., Griffin, K., Wheeler, D., Nitsch, D. (2017). Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit. Nephrology, Dialysis and Transplantation,
Baigent, C., Herrington, W.G., Coresh, J., Landray, M.J., Levin, A., Perkovic, V., ...Wanner, C. (2017). Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. KIDNEY INTERNATIONAL, 92 (2), 297-305. doi:10.1016/j.kint.2017.04.019
Wheeler, D.C., Bockenhauer, D., Day, S., Devuyst, O., Guay-Woodford, L.M., Ingelfinger, J.R., ...Roberts, J. (2017). Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, doi:10.1016/j.kint.2017.06.018
Bello, A.K., Alrukhaimi, M., Ashuntantang, G.E., Basnet, S., Rotter, R.C., Douthat, W.G., ...Powe, N.R. (2017). Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. KIDNEY INTERNATIONAL SUPPLEMENTS, 7 (2), 122-129. doi:10.1016/j.kisu.2017.07.007
Wheeler, D.C., Bello, A.K., Alkhaim, M., Ashuntantang, G., Basnet, S., Rotter, R.C., ...Nangaku, M. (2017). Complications of CKD: current state, knowledge gaps, and strategy for action. Kidney international. Supplement,
Tong, A., Craig, J.C., Nagler, E.V., Van Biesen, W., Manns, B., Hemmelgarn, B., ...Pecoits-Filho, R. (2017). Composing a new song for trials: The Standardized Outcomes in Nephrology (SONG) initiative. Nephrology Dialysis Transplantation, 32 (12), 1963-1966. doi:10.1093/ndt/gfx288
Evangelidis, N., Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D.C., Tugwell, P., ...Winkelmayer, W.C. (2017). Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. AMERICAN JOURNAL OF KIDNEY DISEASES, 70 (4), 464-475. doi:10.1053/j.ajkd.2016.11.029
Wheeler, D.C., Lv, J., Zhang, H., Wong, M.G., Jardine, M.J., Hladunewich, M., ...Barbour, S. (2017). Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA - Journal of the American Medical Association, doi:10.1001/jama.2017.9362
Levin, A., Bonventre, J., Coresh, J., Donner, J.A., Fogo, A.B., Fox, C., ...Kottgen, A. (2017). Global Kidney Health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet, doi:10.1016/S0140-6736(17)30788-2
Wheeler, D.C., Winkelmayer, W.C. (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword. Kidney International Supplements, 7 (1), 12. doi:10.1016/j.kisu.2017.04.001
Storey, B.C., Staplin, N., Haynes, R., Reith, C., Emberson, J., Herrington, W.G., ...Wanner, C. (2017). Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.. Kidney International, doi:10.1016/j.kint.2017.09.011
Wheeler, D.C., Tong, A., Wolfgang, C., van Biesen, W., Tugwell, P., Manns, B., ...Ju, A. (2017). Nephrologists’ perspectives on defining and applying patient-centered outcomes in hemodialysis. CJASN,
Mafham, M.M., Staplin, N., Emberson, J., Haynes, R., Herrington, W., Reith, C., ...Levin, A. (2017). Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.. Nephrol Dial Transplant, doi:10.1093/ndt/gfw396
Judge, P.K., Haynes, R., Herrington, W.G., Storey, B.C., Staplin, N., Bethel, A., ...Dayanandan, R. (2017). Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. Nephrology Dialysis Transplantation, 32 (12), 2043-2051. doi:10.1093/ndt/gfw321
Luyckx, V.A., Tuttle, K.R., Garcia-Garcia, G., Gharbi, M.B., Heerspink, H.J.L., Johnson, D.W., ...Nelson, R.G. (2017). Reducing major risk factors for chronic kidney disease. KIDNEY INTERNATIONAL SUPPLEMENTS, 7 (2), 71-87. doi:10.1016/j.kisu.2017.07.003
Ramesh, S., James, M.T., Holroyd-Leduc, J.M., Wilton, S.B., Seely, E.W., Wheeler, D.C., Ahmed, S.B. (2017). Sex Hormone Status in Women With Chronic Kidney Disease: Survey of Nephrologists' and Renal Allied Health Care Providers' Perceptions.. Canadian journal of kidney health and disease, 4 2054358117734534. doi:10.1177/2054358117734534
Wheeler, D.C., Tomlinson, J.A.P. (2017). The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease. Kidney International,

2016

de Francisco, A.L.M., Gillespie, I.A., Gioni, I., Floege, J., Kronenberg, F., Marcelli, D., ...ARO Steering Committee, C.l.l.a.b.o.r.a.t.o.r.s. (2016). Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 36 (2), 164-175. doi:10.1016/j.nefro.2015.10.006
Evangelidis, N., Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D., Tugwell, P., ...Winkelmayer, W. (2016). Developing a Set of Core Outcomes for Trials in Haemodialysis: An International Delphi Survey.
Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D.C., Evangelidis, N., Tugwell, P., ...O'Donoghue, D. (2016). Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop.. American journal of kidney diseases : the official journal of the National Kidney Foundation,
Herrington, W., Staplin, N., Judge, P., Mafham, M., Emberson, J., Haynes, R., ...Agado, L. (2016). Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension, doi:10.1161/HYPERTENSIONAHA.116.08386
Cleary, F., Nitsch, D., Caplin, B., Wheeler, D.C., Griffith, K., Hull, S., Kim, L. (2016). IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE.
Parfrey, P.S., Block, G.A., Correa-Rotter, R., Drueeke, T.B., Floege, J., Herzog, C.A., ...Wheeler, D.C. (2016). Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 11 (3), 539-546. doi:10.2215/CJN.06370615
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B.R., Levin, A., Thomas, M.C., ...Groop, P.H. (2016). Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.. Kidney Int, 90 (6), 1175-1183. doi:10.1016/j.kint.2016.09.010
Scheppach, J., Cleary, F., Kim, L., Hull, S., Nitsch, D., Wheeler, D.C., Caplin, B. (2016). MORE THAN ONE THIRD OF RENAL PATIENTS UNDER PRIMARY CARE IN THE UK ARE NOT RECEIVING THE RECOMMENDED STATIN THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE.
Urquhart-Secord, R., Craig, J.C., Hemmelgarn, B., Tam-Tham, H., Manns, B., Howell, M., ...Thompson, S. (2016). Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. AMERICAN JOURNAL OF KIDNEY DISEASES, 68 (3), 444-454. doi:10.1053/j.ajkd.2016.02.037
Staplin, N., Haynes, R., Herrington, W.G., Reith, C., Cass, A., Fellström, B., ...Levin, A. (2016). Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).. American journal of kidney diseases : the official journal of the National Kidney Foundation, doi:10.1053/j.ajkd.2016.02.052
Tong, A., Samuel, S., Zappitelli, M., Dart, A., Furth, S., Eddy, A., ...Bockenhauer, D. (2016). Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease.. Trials, 17 401. doi:10.1186/s13063-016-1528-5
Tong, A., Budde, K., Gill, J., Josephson, M.A., Marson, L., Pruett, T.L., ...Warrens, A.N. (2016). Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation.. Transplantation direct, 2 (6), e79.
Wheeler, D.C., Kasiske, B.L. (2016). Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. KIDNEY INTERNATIONAL, 89 (6), 1189-1191. doi:10.1016/j.kint.2016.02.045
Chang, T.I., Abdalla, S., London, G.M., Block, G.A., Correa-Rotter, R., Drueeke, T.B., ...Moe, S.M. (2016). The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. JOURNAL OF HUMAN HYPERTENSION, 30 (3), 204-209. doi:10.1038/jhh.2015.56
Mann, M.C., Exner, D.V., Hemmelgarn, B.R., Hanley, D.A., Turin, T.C., Macrae, J.M., ...Ahmed, S.B. (2016). The VITAH trial—vitamin d supplementation and cardiac autonomic tone in patients with end-stage kidney disease on hemodialysis: A blinded, randomized controlled trial. Nutrients, 8 (10), doi:10.3390/nu8100608
Roberts, M.A., Pilmore, H.L., Ierino, F.L., Badve, S.V., Cass, A., Garg, A.X., ...Perkovic, V. (2016). The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial. American Journal of Kidney Diseases, 67 (6), 902-911. doi:10.1053/j.ajkd.2015.10.029
Jha, V., Arici, M., Collins, A.J., Garcia-Garcia, G., Hemmelgarn, B.R., Jafar, T.H., ...Tchokhonelidze, I. (2016). Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 90 (6), 1164-1174. doi:10.1016/j.kint.2016.09.009

2015

Levin, A., Wheeler, D.C. (2015). A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking. SEMINARS IN DIALYSIS, 28 (6), 654-656. doi:10.1111/sdi.12414
James, M.T., Grams, M.E., Woodward, M., Elley, C.R., Green, J.A., Wheeler, D.C., ...Warnock, D.G. (2015). A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. AMERICAN JOURNAL OF KIDNEY DISEASES, 66 (4), 602-612. doi:10.1053/j.ajkd.2015.02.338
Chapman, A.B., Devuyst, O., Eckardt, K.-.U., Gansevoort, R.T., Harris, T., Horie, S., ...Perrone, R.D. (2015). Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. KIDNEY INTERNATIONAL, 88 (1), 17-27. doi:10.1038/ki.2015.59
Pun, P.H., Abdalla, S., Block, G.A., Chertow, G.M., Correa-Rotter, R., Dehmel, B., ...Herzog, C.A. (2015). Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.. Hemodialysis international. International Symposium on Home Hemodialysis, 20 (3), 421-431.
Moe, S.M., Chertow, G.M., Parfrey, P.S., Kubo, Y., Block, G.A., Correa-Rotter, R., ...Mahaffey, K.W. (2015). Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. CIRCULATION, 132 (1), 27-39. doi:10.1161/CIRCULATIONAHA.114.013876
Palmer, S.C., Mavridis, D., Navarese, E., Craig, J.C., Tonelli, M., Salanti, G., ...Strippoli, G.F.M. (2015). Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. LANCET, 385 (9982), 2047-2056. doi:10.1016/S0140-6736(14)62459-4
Molitch, M.E., Adler, A.I., Flyvbjerg, A., Nelson, R.G., So, W.-.Y., Wanner, C., ...Mogensen, C.E. (2015). Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.. KIDNEY INTERNATIONAL, 87 (1), 20-30. doi:10.1038/ki.2014.128
Wheeler, D.C., London, G.M., Parfrey, P.S., Block, G.A., Correa-Rotter, R., Dehmel, B., ...Mahaffey, K.W. (2015). Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial (vol 3, e001363, 2014). JOURNAL OF THE AMERICAN HEART ASSOCIATION, 4 (1),
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., ...Muntner, P. (2015). Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. The Lancet Diabetes and Endocrinology, 3 (7), 514-525. doi:10.1016/S2213-8587(15)00040-6
Gillespie, I.A., Macdougall, I.C., Richards, S., Jones, V., Marcelli, D., Froissart, M., ...Canaud, B. (2015). Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: Case-crossover study. Pharmacoepidemiology and Drug Safety, 24 (4), 414-426. doi:10.1002/pds.3755
Eckardt, K.-.U., Gillespie, I.A., Kronenberg, F., Richards, S., Stenvinkel, P., Anker, S.D., ...Froissart, M. (2015). High cardiovascular event rates occur within the first weeks of starting hemodialysis. KIDNEY INTERNATIONAL, 88 (5), 1117-1125. doi:10.1038/ki.2015.117
Parfrey, P.S., Block, G.A., Correa-Rotter, R., Drueke, T.B., Floege, J., Herzog, C.A., ...Wheeler, D.C. (2015). Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology, doi:10.2215/CJN.06370615
Gillespie, I.A., Floege, J., Gioni, I., Drueeke, T.B., de Francisco, A.L., Anker, S.D., ...Froissart, M. (2015). Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24 (7), 738-747. doi:10.1002/pds.3789
Tomlinson, J.A.P., Caplin, B.D., Boruc, O., Bruce-Cobbold, C., Cutillas, P., Dormann, D., ...Mas, V.R. (2015). Reduced renal methylarginine metabolism protects against progressive kidney damage. Journal of the American Society of Nephrology, 26 (12), 3045-3059. doi:10.1681/ASN.2014030280
Ketteler, M., Elder, G.J., Evenepoel, P., Ix, J.H., Jamal, S.A., Lafage-Proust, M.-.H., ...Kasiske, B.L. (2015). Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. KIDNEY INTERNATIONAL, 87 (3), 502-508. doi:10.1038/ki.2014.425
Ketteler, M., Elder, G.J., Evenepoel, P., Ix, J.H., Jamal, S.A., Lafage-Proust, M.H., ...Kasiske, B.L. (2015). Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference.
Williams, G.J., Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D.C., Tugwell, P., ...Polkinghorne, K.R. (2015). SCOPE AND CONSISTENCY OF OUTCOMES REPORTED IN RANDOMISED TRIALS OF HAEMODIALYSIS. NEPHROLOGY, 20 27.
Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D.C., Tugwell, P., Winkelmayer, W.C., ...Polkinghorne, K.R. (2015). Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. TRIALS, 16 doi:10.1186/s13063-015-0895-7
Parfrey, P.S., Drueeke, T.B., Block, G.A., Correa-Rotter, R., Floege, J., Herzog, C.A., ...Wheeler, D.C. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 10 (5), 791-799. doi:10.2215/CJN.07730814
Mann, M.C., Exner, D.V., Hemmelgarn, B.R., Hanley, D.A., Turin, T.C., Sola, D.Y., ...Ahmed, S.B. (2015). VITAMIN D SUPPLEMENTATION IS ASSOCIATED WITH IMPROVED MODULATION OF CARDIAC AUTONOMIC TONE IN IGA NEPHROPATHY.
Mann, M.C., Hemmelgarn, B.R., Exner, D.V., Hanley, D.A., Turin, T.C., Wheeler, D.C., ...Ahmed, S.B. (2015). Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy. HYPERTENSION, 66 (2), E4-E6. doi:10.1161/HYPERTENSIONAHA.115.05688

2014

Power, A., Fogarty, D., Wheeler, D.C. (2014). Acute stroke thrombolysis in end-stage renal disease: a national survey of nephrologist opinion.. Nephron Clinical Practice, 124 (3-4), 167-172. doi:10.1159/000357155
Caplin, B., Wheeler, D.C. (2014). Chronic kidney disease: Cardiovascular complications. In Practical Nephrology. (pp. 589-601). .
Wheeler, D.C., London, G.M., Parfrey, P.S., Block, G.A., Correa-Rotter, R., Dehmel, B., ...Mahaffey, K.W. (2014). Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (6), doi:10.1161/JAHA.114.001363
Moe, S.M., Abdalla, S., Chertow, G.M., Parfrey, P., Block, G.A., Correa-Rotter, R., ...Mahaffey, K.W. (2014). Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Journal of the American Society of Nephrology, doi:10.1681/ASN.2014040414
Haynes, R., Lewis, D., Emberson, J., Reith, C., Agodoa, L., Cass, A., ...Fellström, B. (2014). Effects of lowering LDL cholesterol on progression of kidney disease.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 25 (8), 1825-1833. doi:10.1681/ASN.2013090965
Chen, Y., Ku, H., Zhao, L., Wheeler, D.C., Li, L.-.C., Li, Q., ...Huang, A. (2014). Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 34 (2), 365-376. doi:10.1161/ATVBAHA.113.301301
Chen, Y., Zhao, L., Li, Q., Wheeler, D.C., Varghese, Z., Moorhead, J.F., ...Ruan, X.Z. (2014). Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 29 (10), 1864-1878. doi:10.1093/ndt/gfu203
Wheeler, D.C., Becker, G. (2014). Is intensive blood pressure lowering justifiable in CKD?. AMERICAN JOURNAL OF KIDNEY DISEASES, 63 (6), 903-905. doi:10.1053/j.ajkd.2014.03.007
Deanfield, J., Simpson, I., Bradbury, K., Fox, K., Boon, N., Winocour, P., ...Jennings, C. (2014). Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). HEART, 100 1-67. doi:10.1136/heartjnl-2014-305693
Kasiske, B.L., Wheeler, D.C. (2014). Kidney Disease: Improving Global Outcomes--an update.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 29 (4), 763-769. doi:10.1093/ndt/gft441
Wen, C.P., Matsushita, K., Coresh, J., Iseki, K., Islam, M., Katz, R., ...De Zeeuw, D. (2014). Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney International, 86 (4), 819-827. doi:10.1038/ki.2013.553
Wheeler, D.C., Abdalla, S., Chertow, G., Parfrey, P., Herzog, C. (2014). THE EFFECT OF CINACALCET ON ATHEROSCLEROTIC AND NON-ATHEROSCLEROTIC EVENTS IN HAEMODIALYSIS PATIENTS IN THE EVOLVE CLINICAL TRIAL.

2013

Fish, R.S., Klootwijk, E., Tam, F.W.K., Kleta, R., Wheeler, D.C., Unwin, R.J., Norman, J. (2013). ATP and arterial calcification. European Journal of Clinical Investigation, 43 (4), 405-412. doi:10.1111/eci.12055
Fish, R.S., Klootwijk, E., Tam, F.W.K., Kleta, R., Wheeler, D.C., Unwin, R.J., Norman, J. (2013). ATP and arterial calcification.. European Journal of Clinical Investigation, Epub ahead of print doi:10.1111/eci.12055
Haynes, R., Wheeler, D.C. (2013). Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?. NATURE REVIEWS NEPHROLOGY, 9 (8), 438-439. doi:10.1038/nrneph.2013.128
Parfrey, P., Block, G., Chertow, G.M., Correa-Rotter, R., Dehmel, B., Drueke, T.B., ...Mahaffey, K.W. (2013). DISEASE PROGRESSION AND SURGICAL PARATHYROIDECTOMY (PTX) IN THE EVOLVE TRIAL.
Caplin, B., Veighey, K., Mahenderan, A., Manook, M., Henry, J., Nitsch, D., ...Jones, G. (2013). Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function.. Clin Transplant, 27 (6), E669-E678. doi:10.1111/ctr.12251
Tonelli, M.A., Wanner, C., Cass, A., Garg, A.X., Holdaas, H., Jardine, A.G., ...Shoji, T. (2013). Introduction: The case for updating and context. KIDNEY INTERNATIONAL SUPPLEMENTS, 3 (3), 266-+. doi:10.1038/kisup.2013.32
Kasiske, B.L., Wheeler, D.C. (2013). KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Foreword. KIDNEY INTERNATIONAL SUPPLEMENTS, 3 (3), 260. doi:10.1038/kisup.2013.28
Kasiske, B.L., Wheeler, D.C. (2013). KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword. KIDNEY INTERNATIONAL SUPPLEMENTS, 3 (1), 2. doi:10.1038/kisup.2012.74
Chan, C.T., Covic, A., Craig, J.C., Davenport, A., Kasiske, B.L., Kuhlmann, M.K., ...Rocco, M.V. (2013). Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes.. KIDNEY INTERNATIONAL, 83 (3), 359-371. doi:10.1038/ki.2012.450
Block, G.A., Ix, J.H., Ketteler, M., Martin, K.J., Thadhani, R.I., Tonelli, M., ...Wheeler, D.C. (2013). Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.. AMERICAN JOURNAL OF KIDNEY DISEASES, 62 (3), 457-473. doi:10.1053/j.ajkd.2013.03.042
Wheeler, D.C., Becker, G.J. (2013). Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. KIDNEY INTERNATIONAL, 83 (3), 377-383. doi:10.1038/ki.2012.425
Parfrey, P.S., Chertow, G.M., Block, G.A., Correa-Rotter, R., Drüeke, T.B., Floege, J., ...Moe, S.M. (2013). The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 98 (12), 4834-4844. doi:10.1210/jc.2013-2975
Kasiske, B.L., Wheeler, D.C. (2013). The management of dyslipidemia in CKD: new analyses of an expanding dataset.. AMERICAN JOURNAL OF KIDNEY DISEASES, 61 (3), 371-374. doi:10.1053/j.ajkd.2012.11.035

2012

Hallan, S.I., Matsushita, K., Sang, Y., Mahmoodi, B.K., Black, C., Ishani, A., ...Tonelli, M. (2012). Age and association of kidney measures with mortality and end-stage kidney disease. JAMA: Journal of the American Medical Association, 308 (22), 2349-2360. doi:10.1001/jama.2012.16817
Caplin, B., Wang, Z., Slaviero, A., Tomlinson, J., Dowsett, L., Delahaye, M., ...Leiper, J. (2012). Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure.. Arterioscler Thromb Vasc Biol, Epub ahead of print doi:10.1161/ATVBAHA.112.254078
Fox, C.S., Matsushita, K., Woodward, M., Bilo, H.J., Chalmers, J., Heerspink, H.J., ...Sairenchi, T. (2012). Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet, 380 (9854), 1662-1673. doi:10.1016/S0140-6736(12)61350-6
Mahmoodi, B.K., Matsushita, K., Woodward, M., Blankestijn, P.J., Cirillo, M., Ohkubo, T., ...Yamagishi, K. (2012). Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet, 380 (9854), 1649-1661. doi:10.1016/S0140-6736(12)61272-0
Chertow, G.M., Correa-Rotter, R., Block, G.A., Drueke, T.B., Floege, J., Goodman, W.G., ...Mahaffey, K.W. (2012). Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 27 (7), 2872-2879. doi:10.1093/ndt/gfr777
Wheeler, D.C., Haynes, R., Landry, M.J., Baigent, C. (2012). Cardiovascular aspects of kidney disease. In Taal, M.W., Chertow, G.M., Marseden, P.A., Skorecki, K., Yu, A.S.L., Brenner, B.M. (Eds.), Brenner and Rector's the Kidney. (pp. 2059-2080). Philadelphia, USA: Elsevier Saunders.
Nitsch, D., Wheeler, D.C. (2012). Community-based strategies for blood pressure control in low-income countries.. AMERICAN JOURNAL OF KIDNEY DISEASES, 60 (3), 347-349. doi:10.1053/j.ajkd.2012.02.319
Matsushita, K., Mahmoodi, B.K., Woodward, M., Emberson, J.R., Jafar, T.H., Jee, S.H., ...Tonelli, M. (2012). Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA: Journal of the American Medical Association, 307 (18), 1941-1951. doi:10.1001/jama.2012.3954
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D.W., Woodward, M., ...TESTING Study Group [Wheeler DC, Testing Steering Group, m.e.m.b.e.r.]. (2012). Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol, 23 (6), 1108-1116. doi:10.1681/ASN.2011111112
Girfoglio, D., Allen, D., Kirkham, A., Johri, N., Wheeler, D.C., Choong, S., ...Unwin, R. (2012). CT SCAN EVALUATION OF PAPILLARY DENSITY IN HYPERCALCIURIC AND NON-HYPERCALCIURIC STONE FORMERS.
EVOLVE Trial, I.n.v.e.s.t.i.g.a.t.o.r.s., Chertow, G.M., Block, G.A., Correa-Rotter, R., Drüeke, T.B., Floege, J., ...London, G.M. (2012). Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.. New Engl J Med, epub ahead of print doi:10.1056/NEJMoa1205624
Block, G.A., Wheeler, D.C., Persky, M.S., Kestenbaum, B., Ketteler, M., Spiegel, D.M., ...Hoofnagle, A.N. (2012). Effects of Phosphate Binders in Moderate CKD. JASN, 23 (8), 1407-1415. doi:10.1681/ASN.2012030223
Kasiske, B.L., Wheeler, D.C. (2012). Foreword. KIDNEY INTERNATIONAL SUPPLEMENTS, 2 (4), 280. doi:10.1038/kisup.2012.38
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group [Wheeler DC, Work Group, C.o.-.C.h.a.i.r.]. (2012). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International, Suppl 2 337-414.
Wheeler, D.C., Caplin, B. (2012). New observational data demonstrate that mortality is lower in patients receiving more frequent dialysis.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 23 (5), 770-773. doi:10.1681/ASN.2012030311
Torres, V.E., Chapman, A.B., Devuyst, O., Gansevoort, R.T., Grantham, J.J., Higashihara, E., ...Czerwiec, F.S. (2012). Tolvaptan in patients with autosomal dominant polcystic kidney disease. New England Journal of Medicine, 367 (25), 2407-2418. doi:10.1056/NEJMoa1205511
Neild, G.H., Hughes, T.D., Booth, J.W., Wheeler, D.C. (2012). Tuberculous pyomyositis in a renal transplant recipient.. Clinical kidney journal, 5 (4), 367-368. doi:10.1093/ckj/sfs075

2011

de Francisco, A.L.M., Kim, J., Anker, S.D., Belozeroff, V., Canaud, B., Chazot, C., ...Kronenberg, F. (2011). An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study.. NEPHRON CLINICAL PRACTICE, 118 (2), C143-C154. doi:10.1159/000319936
Griffiths, P.D., Stanton, A., McCarrell, E., Smith, C., Osman, M., Harber, M., ...O'Beirne, J. (2011). Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.. LANCET, 377 (9773), 1256-1263. doi:10.1016/S0140-6736(11)60136-0
Lameire, N., Wheeler, D.C., Floege, J. (2011). Editorial report 2010.. Nephrol Dial Transplant, 26 (1), 1-3. doi:10.1093/ndt/gfq754
Astor, B.C., Matsushita, K., Gansevoort, R.T., van der Velde, M., Woodward, M., Levey, A.S., ...Astor, B.C. (2011). Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.. Kidney Int, doi:10.1038/ki.2010.550
Haynes, R., Hutchison, C.A., Emberson, J., Dasgupta, T., Wheeler, D.C., Townend, J.N., ...Cockwell, P. (2011). Serum free light chains and the risk of ESRD and death in CKD.. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 6 (12), 2829-2837. doi:10.2215/CJN.03350411
Floege, J., Kim, J., Ireland, E., Chazot, C., Drueke, T., de Francisco, A., ...Schernthaner, G. (2011). Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 26 (6), 1948-1955. doi:10.1093/ndt/gfq219
Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., ...Craig, J. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.. LANCET, 377 (9784), 2181-2192. doi:10.1016/S0140-6736(11)60739-3

2010

Becker, G.J., Wheeler, D.C. (2010). Blood Pressure Control in CKD Patients: Why Do We Fail to Implement the Guidelines?. AMERICAN JOURNAL OF KIDNEY DISEASES, 55 (3), 415-418. doi:10.1053/j.ajkd.2009.12.013
Levin, N.W., Kotanko, P., Eckardt, K.-.U., Kasiske, B.L., Chazot, C., Cheung, A.K., ...London, G.M. (2010). Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. KIDNEY INTERNATIONAL, 77 (4), 273-284. doi:10.1038/ki.2009.469
Caplin, B., Nitsch, D., Gill, H., Hoefield, R., Blackwell, S., MacKenzie, D., ...Veitch, P. (2010). Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.. KIDNEY INTERNATIONAL, 77 (5), 459-467. doi:10.1038/ki.2009.463
Wheeler, D.C. (2010). Clinical evaluation and management of chronic kidney disease. In Feehally, J., Floege, J., Johnson, R. (Eds.), Comprehensive clinical nephrology. (pp. 927-934). Philadelphia, USA: Elsevier Saunders.
Landray, M.J., Emberson, J.R., Blackwell, L., Dasgupta, T., Zakeri, R., Morgan, M.D., ...Nair, D. (2010). Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.. AMERICAN JOURNAL OF KIDNEY DISEASES, 56 (6), 1082-1094. doi:10.1053/j.ajkd.2010.07.016
Tomlinson, L., Ben-Shlomo, Y., Caplin, B., Delles, C., Ferro, C.J., Goddard, J., ...Mceniery, C.M. (2010). RENAL DISEASE IS ASSOCIATED WITH ACCELERATED VASCULAR AGEING: INITIAL RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION.
SHARP Collaborative Group [Wheeler DC, Member of International Steering Committee and UK, C.o.-.o.r.d.i.n.a.t.o.r.]. (2010). Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. American Heart Journal, (160), 785-794.e10. doi:10.1016/j.ahj.2010.08.012
Lameire, N., Floege, J., Wheeler, D.C. (2010). The five most cited NDT papers from 2005 to 2009.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 25 (9), 2825-2831. doi:10.1093/ndt/gfq464

2009

Block, G.A., Persky, M.S., Ketteler, M., Kestenbaum, B., Thadhani, R., Kooienga, L., ...Dennis, V. (2009). A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. HEMODIALYSIS INTERNATIONAL, 13 (3), 360-362. doi:10.1111/j.1542-4758.2009.00387.x
Wheeler, D.C. (2009). C-reactive protein and statins: by Jupiter! Reply. NEPHROLOGY DIALYSIS TRANSPLANTATION, 24 (11), 3552. doi:10.1093/ndt/gfp402
Moe, S.M., Drueeke, T.B., Block, G.A., Cannata-Andia, J.B., Elder, G.J., Fukagawa, M., ...Levin, A. (2009). Introduction and definition of CKD-MBD and the development of the guideline statements. KIDNEY INTERNATIONAL, 76 S3-S130. doi:10.1038/ki.2009.189
Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group [Wheeler DC Workgroup, M.e.m.b.e.r.]. (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD). Kidney Int, (Suppl. 113), S1-S130.
Wheeler, D.C. (2009). The Jupiter trial--new territory for statins?. NEPHROLOGY DIALYSIS TRANSPLANTATION, 24 (7), 2036-2037. doi:10.1093/ndt/gfp237

2008

Locatelli, F., Nissenson, A.R., Barrett, B.J., Walker, R.G., Wheeler, D.C., Eckardt, K.U., ...Eknoyan, G. (2008). Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).. KIDNEY INTERNATIONAL, 74 (10), 1237-1240. doi:10.1038/ki.2008.299
Mactier, R., Wheeler, D.C. (2008). General management of the haemodialysis patient. In Malony, D., Craig, J.C. (Eds.), Evidence-based nephrology. (pp. 431-440). Wiley-Blackwell.
Rahman, E.U., R.u.a.n., X, Z., C.h.a.n.a., R, S., B.r.u.n.s.k.i.l.l., ......P.o.w.i.s. (2008). Mesangial matrix-activated monocytes express functional scavenger receptors and accumulate intracellular lipid. Nephrology Dialysis Transplantation, 23 1876-1885.
Lameire, N., Wheeler, D.C., Floege, J. (2008). Salt wars.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 23 (9), 2715. doi:10.1093/ndt/gfn460
Lameire, N., Floege, J., Wheeler, D.C. (2008). Untitled. NEPHROLOGY DIALYSIS TRANSPLANTATION, 23 (9), 2716. doi:10.1093/ndt/gfn410

2007

Caplin, B., Wheeler, D.C. (2007). Arterial calcification in dialysis patients and transplant recipients.. SEMINARS IN DIALYSIS, 20 (2), 144-149. doi:10.1111/j.1525-139X.2007.00262.x
Lameire, N., Floege, J., Wheeler, D.C. (2007). Changes to the Editorial Board and the launch of NDTplus. NEPHROLOGY DIALYSIS TRANSPLANTATION, 22 (7), 1805. doi:10.1093/ndt/gfm412
Levey, A.S., Atkins, R., Coresh, J., Cohen, E.P., Collins, A.J., Eckardt, K.-.U., ...Levin, A. (2007). Chronic kidney disease as a global public health problem: Approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. KIDNEY INTERNATIONAL, 72 (3), 247-259. doi:10.1038/sj.ki.5002343
Wheeler, D.C., Winearls, C.G. (2007). Clinical evaluation and management of chronic kidney disease. In Feehally, J., Floege, J., Johnson, R. (Eds.), Comprehensive clinical nephrology. (pp. 831-838). Philadelphia, USA: Mosby Elsevier.
Zehnder, D., Landray, M.J., Wheeler, D.C., Fraser, W., Blackwell, L., Nuttall, S., ...Baigent, C. (2007). Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study.. NEPHRON CLINICAL PRACTICE, 107 (3), C109-C116. doi:10.1159/000108652
Chertow, G.M., Pupim, L.B., Block, G.A., Correa-Rotter, R., Drueke, T.B., Floege, J., ...Moe, S.M. (2007). Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2 (5), 898-905. doi:10.2215/CJN.04381206
Baigent, C., Landray, M.J., Wheeler, D.C. (2007). Misleading associations between cholesterol and vascular outcomes in dialysis patients: The need for randomized trials. SEMINARS IN DIALYSIS, 20 (6), 498-503. doi:10.1111/j.1525-139X.2007.00340.x
Wheeler, D.C., Krentz, A.J. (2007). New-onset diabetes after transplanation. BRITISH JOURNAL OF HOSPITAL MEDICINE, 68 (4), 190-194. doi:10.12968/hmed.2007.68.4.190
Lameire, N., Floege, J., Wheeler, D.C. (2007). Report from the editorial office. NEPHROLOGY DIALYSIS TRANSPLANTATION, 22 (1), 1-2. doi:10.1093/ndt/gfl773
Ruan, X.Z., Wheeler, D.C., Hunt, J., Powis, S.H., Varghese, Z., Moorhead, J.F. (2007). SCAP-mediated dysregulation of LDL receptor under inflammatory stress: A potential new pathway for foam cell formation.

2006

Ruan, X., Moorhead, J.F., Tao, J.L., Ma, K.L., Wheeler, D.C., Powis, S.H., Varghese, Z. (2006). Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines.. Arteriosclerosis, Thrombosis, and Vascular Biology, 26 (5), 1150-1155. doi:10.1161/01.ATV.0000217957.93135.c2
Wheeler, D.C., Floege, J., Lameire, N. (2006). NDT contributes to a collection of 100 seminal papers published by Oxford University Press. NEPHROLOGY DIALYSIS TRANSPLANTATION, 21 (8), 2047-2048. doi:10.1093/ndt/gfl441
Lameire, N., Floege, J., Wheeler, D.C. (2006). Report from the editorial office. NEPHROLOGY DIALYSIS TRANSPLANTATION, 21 (1), 1. doi:10.1093/ndt/gfi349
Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., ...Cairns, H.S. (2006). The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. AMERICAN JOURNAL OF KIDNEY DISEASES, 47 (3), 385-395. doi:10.1053/j.ajkd.2005.11.018
Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., ...Cairns, S. (2006). The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.. American Journal of Kidney Diseases, 47 (3), 385-395. doi:10.1053/j.ajkd.2005.11.018

2005

Homocysteine Lowering Trialists Collaboration [Wheeler DC, Homocysteine LTC, m.e.m.b.e.r.]. (2005). Dose-dependent effects of oflic acid on blood concentrations of homocysteine: a meta-analysis of randomised trials. American Journal of Clinical Nutrition, 82 806-812.
Landray, M.J., Dalton, N., Turner, C., Blackwell, L., Morgan, M., Nuttall, S., ...Wheeler, D.C. (2005). ELEVATED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) AND SYMMETRIC DIMETHYLARGININE (SDMA) CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS.
Landray, M.J., Ayrton, P., Blackwell, L., Nuttall, S., Nair, D., Townend, J., ...Wheeler, D.C. (2005). ELEVATED LEVELS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE AND TROPONIN T CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS.
Li, H., Ruan, X.Z., Powis, S.H., Fernando, R., Mon, W.Y., Wheeler, D.C., ...Varghese, Z. (2005). EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism.. Kidney International, 67 (3), 867-874. doi:10.1111/j.1523-1755.2005.00151.x
Baigent, C., Landray, M., Leaper, C., Altmann, P., Armitage, J., Baxter, A., ...Frighi, V. (2005). First United Kingdom Heart and Renal Protection (UK-HARP-1) study: Biochemical efficacy and safety of simvastatin and safety of low dose aspirin in chronic kideny disease.. American Journal of Kidney Diseases, 45 473-484.
Langman, C.B., Salusky, I.B., Greenbaum, L., Jueppner, H., Leonard, M., Nelson, P., ...Oppenheim, W.L. (2005). K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group membership. American Journal of Kidney Diseases, 46 (SUPPL. 1), doi:10.1053/j.ajkd.2005.07.028
Krentz, A.J., Wheeler, D.C. (2005). New-onset diabetes after transplantation: a threat to graft and patient survival. The Lancet, 365 640-642.
Lameire, N., Floege, J., Wheeler, D.C. (2005). Report from the Editorial Office. NEPHROLOGY DIALYSIS TRANSPLANTATION, 20 (10), 2019-2021. doi:10.1093/ndt/gfi122
Landray, M.J., Blackwell, L., Morgan, M., Nuttall, S., Baigent, C., Townend, J., Wheeler, D.C. (2005). SERUM LIPIDS DO NOT PREDICT CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS.

2004

Kasiske, B., Cosio, F.G., Beto, J., Bolton, K., Chavers, B.M., Grimm R, J.R., ...Wanner, C. (2004). Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.. American Journal of Transplantation, 4 (7), 13-53.
Wheeler, D.C. (2004). Does lipid-lowering therapy slow progression of chronic kidney disease?. American Journal of Kidney Diseases, 44 (5), 917-920.
Landray, M.J., Wheeler, D.C., Lip, G.Y., Newman, D.J., Blann, A.D., McGlynn, F.J., ...Baigent, C. (2004). Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study.. American Journal of Kidney Diseases, 43 (2), 244-253.
Jones, G., Wheeler, D., Davenport, A. (2004). Quiz page February 2004. American Journal of Kidney Diseases, 43 (2),
Jones, G., Wheeler, D., Davenport, A. (2004). Quiz page. Severe metabolic acidosis, caused by an enteric augmentation of urinary tract and renal impairment. Decompensation was caused by lack of self-catheterization.. American journal of kidney diseases : the official journal of the National Kidney Foundation, 43 (2),
Ruan, X.Z., Moorhead, J.F., Fernando, R., Wheeler, D.C., Powis, S.H., Varghese, Z. (2004). Regulation of lipoprotein trafficking in the kidney: role of inflammatory mediators and transcription factors.. Biochemical Society Transactions, 32 (1), 88-91.
George, S., Ruan, X.Z., Navarrete, C., Turner, D., Reynard, M., Sweny, P., ...Moorhead, J.F. (2004). Renovascular disease is associated with low producer genotypes of the anti-inflammatory cytokine interleukin-10.. Tissue Antigens, 63 (5), 470-475.
Thompson, B.C., Kingdon, E., Johnston, M., Tibballs, J., Watkinson, A., Jarmulowicz, M., ...Wheeler, D.C. (2004). Transjugular kidney biopsy.. American Journal of Kidney Diseases, 43 (4), 651-662.
Wheeler, D.C. (2004). Uraemia and cardiovascular risk. In Franklyn, J. (Ed.), Horizons in medicine. (pp. 113-119). London, UK: Royal College of Physicians of London.

2003

Varghese, Z., Fernando, R., Moorhead, J.F., Powis, S.H., Wheeler, D.C., Ruan, X.Z. (2003). Anti-atherosclerotic effects of sirolimus: Dual actions on both cholesterol Homeostasis and inflammmation..
Wheeler, D.C., Townend JN, L.M.J. (2003). Cardiovascular risk factors in predialysis patients: baseline date from the Chronic Renal Impairment in Birmingham (CRIB) study.. Kidney International, 75 S201-S203.
Wheeler, D.C. (2003). Detection of sub-clinical vascular disease: A little help from the kidney. Nephron Clinical Practice, 93 (C85), C86-.
Wheeler, D.C. (2003). Detection of sub-clinical vascular disease: a little help from the kidney.. NEPHRON CLINICAL PRACTICE, 93 (3), C85-C86. doi:10.1159/000069550
Ruan, X.Z., Moorhead, J.F., Powis, S.H., Fernando, R., Wheeler, D.C., Varghese, Z. (2003). Dysregulation of LDL receptor by an inflammatory cytokine: A new pathway for foam cell formation in vascular smooth muscle cells..
Ruan, X.Z., Moorhead, J.F., Powis, S.H., Fernando, R., Wheeler, D.C., Varghese, Z. (2003). Dysregulation of LDL receptor by inflammatory cytokines: A new pathway for foam cell formation in vascular smooth muscle cells (VSMCS).
National Kidney Foundation [Wheeler DC, K/DOQI, m.e.m.b.e.r.]. (2003). K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease.. American Journal of Kidney Diseases, 41 S1-S92.
Wheeler, D.C. (2003). Management of the diabetic with advanced and end stage renal disease. In Brady, H., Wilcox, D. (Eds.), Therapy in nephrology and hypertension. (pp. 327-332). Philadelphia, USA: Harcourt Health Sciences.
Rahman, E.U., Chana, R.S., Ruan, X.Z., Powis, S.H., Varghese, Z., Wheeler, D.C. (2003). Mesangial matrix-activated mononuclear cells express functional scavenger receptors and accumulate intracellular lipid..
Chana, R.S., Martin, J., Rahman, E.U., Wheeler, D.C. (2003). Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production. Kidney International, 63 (3), 889-898. doi:10.1046/j.1523-1755.2003.00828.x
Davidson, J., Wilkinson, A., Dantal, J., Dotta, F., Haller, H., Hernandez, D., ...Legendre, C. (2003). New onset diabetes after transplantation: 2003 International consensus guidelines.. Transplantation, 75 (10), SS3-SS24.
Li, H., Ruan, X.Z., Moorhead, J.F., Powis, S.H., Fernando, R., Wheeler, D.C., Varghese, Z. (2003). omega 3 Polyunsaturated fatty acids (PUFA) inhibit NF-kappa B activity in LPS-Stimulated proximal tubular cells by PPAR gamma activation..
Ruan, X., Moorhead, J.F., Fernando, R., Wheeler, D.C., Powis, S.H., Varghese, Z. (2003). PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. Journal of the American Society of Nephrology, 14 (3), 593-600. doi:10.1097/01.ASN.0000050414.52908.DA
Wheeler, D.C. (2003). Statins in chronic kidney disease: effective anti-inflammatory agents?. Nephron Clinical Practice, 94 c105-c106.
Nuttall, S.L., Landray, M.J., Townend, J.N., Ball, S., Wheeler, D.C. (2003). Two-year survival among patients with chronic-kidney disease not on dialysis: The chronic renal impairment in Birmingham (CRIB) study..

2002

Harris, K.P.G., Wheeler, D.C., Chong, C.C. (2002). A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International, 61 (4), 1469-1474.
Ruan, X.Z., Moorhead, J.F., Fernando, R., Wheeler, D.C., Powis, S.H., Varghese, Z. (2002). CREB binding protein (CBP) is an essential factor that controls cholesterol accumulation and efflux in human mesangial cells (HMCs).
Rahman, E.U., Ruan, X.Z., Fernando, R.L., Varghese, Z., Powis, S.H., Wheeler, D.C. (2002). Human mesangial matrix stimulates production of inflammatory cytokines and induces scavenger receptor expression in THP-1 monocytes.
Zehnder, D., Bland, R., Chana, R.S., Wheeler, D.C., Howie, A.J., Williams, M.C., ...Hewison, M. (2002). Synthesis of 1,25-dihydroxyvitamin D-3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. Journal of the American Society of Nephrology, 13 (3), 621-629.
Thompson, B.C., Kingdon, E.J., Watkinson, A.J., Wheeler, D.C. (2002). The use of transjugular renal biopsy in high risk patients..
Thompson, B.C., Kingdon, E.J., Watkinson, A.J., Wheeler, D.C. (2002). The use of transjugular renal biopsy in high risk patients..

2001

Thambyrajah, J., Landray, M.J., Jones, H.J., McGlynn, F.J., Wheeler, D.C., Townend, J.N. (2001). A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. Journal of the American College of Cardiology, 37 (7), 1858-1863. doi:10.1016/S0735-1097(01)01235-9
Holdaas, H., Jardine, A.G., Wheeler, D.C., Brekke, I.B., Conlon, P.J., Fellstrom, B., ...Moore, R. (2001). Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International, 60 (5), 1990-1997.
Landray, M.J., Thambyrajah, J., McGlynn, F.J., Jones, H.J., Baigent, C., Kendall, M.J., ...Wheeler, D.C. (2001). Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. American Journal of Kidney Diseases, 38 (3), 537-546.
Wheeler, D.C. (2001). Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. Journal of Nephrology, 14 Sup S70-S75.
Zehnder, D., Bland, R., Wheeler, D.C., Stewart, P.M., Hewison, M. (2001). Synthesis of 1,25-dihydroxyvitamin D-3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion.. JOURNAL OF BONE AND MINERAL RESEARCH, 16 S310.
Nuttall, S.L., Kendall, M.J., Townend, J.N., Wheeler, D.C. (2001). Vitamin E supplementation. The Lancet, 357 (9256), 631-633.

2000

Thambyrajah, J., Landray, M.J., Wheeler, D.C., Townend, J.N. (2000). A randomised trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. CIRCULATION, 102 (18), 703.
Thambyrajah, J., Landray, M.J., McGlynn, F.J., Jones, H.J., Wheeler, D.C., Townend, J.N. (2000). Abnormalities of enodthelial function in patients with predialysis renal failure. Heart, 83 205-209.
Wheeler, D.C., Baigent, C. (2000). Cardiovascular risk factors in patients with chronic renal failure. In Loscalzo, J., London, G. (Eds.), Cardiovascular disease in end-stage renal failure. (pp. 3-28). Oxford, UK: Oxford University Press.
Thambyrajah, J., Landray, M.J., McGlynn, F.J., Jones, H.J., Wheeler, D.C., Townend, J.N. (2000). Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?. Circulation, 102 (8), 871-875.
Thambyrajah, J., Landray, M.J., McGlynn, F.J., Jones, H.J., Wheeler, D.C., Townend, J.N. (2000). Does folic acid decrease plasma homocysteine and improve endothelial function in pre-dialysis renal failure?. Circulation, 102 871-875.
Wheeler, D.C., Steiger, J. (2000). Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation, 70 (11 Sup), SS41-SS45.
Majumdar, A., Wheeler, D.C. (2000). Lipid abnormalities in renal disease. Journal of the Royal Society of Medicine, 93 (4), 178-182.
Chana, R.S., Wheeler, D.C., Thomas, G.J., Williams, J.D., Davies, M. (2000). Low-density lipoprotein stimulates mesangial cell proteoglycan and hyaluronan synthesis. Nephrology Dialysis Transplantation, 15 (2), 167-172.
Baigent, C., Burbury, K., Wheeler, D.C. (2000). Premature cardiovascular disease in chronic renal failure. The Lancet, 356 147-152.
Baigent, C., Wheeler, D.C. (2000). Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?. Nephrology Dialysis Transplantation, 15 (8), 1118-1119.

1999

Webber, J., Wheeler, D.C., Ryder, R.E.J., Taylor, K.G., Jones, S.L. (1999). Ethnic differences in a diabetic renal clinic in Birmingham, UK. DIABETOLOGIA, 42 A277.
Chana, R.S., Wheeler, D.C. (1999). Fibronectin augments monocyte adhesion to low-density lipoprotein-stimulated mesangial cells.. KIDNEY INTERNATIONAL, 55 (1), 179-188. doi:10.1046/j.1523-1755.1999.00250.x
Wheeler, D.C. (1999). Ischaemic heart disease after renal transplantation: how to assess and minimize the risk.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 14 (5), 1075-1077. doi:10.1093/ndt/14.5.1075
Landray, M.J., Townend, J.N., Martin, S., Martin, U., Wheeler, D.C. (1999). Lipid-lowering drugs and homocysteine.. LANCET, 353 (9168), 1974-1975. doi:10.1016/S0140-6736(05)77189-0
Eardley, K., Majumdar, A., Ferrreira, M.A.S., Howie, A.J., Richards, N.T., Savage, C.O.S., ...Lipkin, G.W. (1999). Microalbuminuria as a predictor of glomerular disease and renal prognosis in patients with microscopic haematuria.. KIDNEY INTERNATIONAL, 55 (6), 2586.
Chana, R.S., Wheeler, D.C. (1999). Monocyte adhesion to mesangial matrix stimulates cytokine production.. KIDNEY INTERNATIONAL, 55 (6), 2585.
Majumdar, A., Eardley, K., Howie, A.J., Savage, C.O.S., Wheeler, D.C., Richards, N.T., ...Lipkin, G.W. (1999). Prevalence, predictors and prognostic significance of non-diabetic renal disease (NDRD) in patients with type II diabetes mellitus (NIDM).. KIDNEY INTERNATIONAL, 55 (6), 2592.
Chana, R.S., Milford, D.V., Pawluczyk, I.Z.A., Wheeler, D.C. (1999). Tacrolimus inhibits TGF-beta-mediated fibronectin production by human mesangial cells.. KIDNEY INTERNATIONAL, 55 (5), 2104.
Majumdar, A., Lipkin, G.W., Eliott, T.S., Wheeler, D.C. (1999). Vancomycin-dependent enterococci in a uraemic patient with sclerosing peritonitis.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 14 (3), 765-767. doi:10.1093/ndt/14.3.765

1998

Wheeler, D.C. (1998). Are there potential non-lipid-lowering uses of statins?. DRUGS, 56 (4), 517-522. doi:10.2165/00003495-199856040-00001
Rajman, I., Harper, L., McPake, D., Kendall, M.J., Wheeler, D.C. (1998). Low-density lipoprotein subfraction profiles in chronic renal failure.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 13 (9), 2281-2287. doi:10.1093/ndt/13.9.2281
Lim, A.K., Ferreira, M.A., Majumdar, A., Wheeler, D.C., Lipkin, G.W. (1998). Renal amyloidosis and angioimmunoblastic lymphadenopathy.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 13 (2), 453-454.
Wheeler, D.C. (1998). Statins and the kidney.. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 7 (5), 579-584. doi:10.1097/00041552-199809000-00015

1997

Tse, W.Y., Howie, A.J., Adu, D., Savage, C.O., Richards, N.T., Wheeler, D.C., Michael, J. (1997). Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 12 (5), 1017-1027. doi:10.1093/ndt/12.5.1017
Chana, R.S., Savage, C.O.S., Wheeler, D.C. (1997). Fibronectin augments monocyte adhesion to lipoprotein-stimulated human mesangial cells..
Harper, L., Cockwell, P., Howie, A.J., Michael, J., Richards, N.T., Savage, C.O., ...Adu, D. (1997). Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis.. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 90 (2), 125-132. doi:10.1093/qjmed/90.2.125
Channa, R.S., Wheeler, D.C. (1997). Low density lipoprotein enhances monocyte bonding to human mesangial cells.
Wheeler, D.C. (1997). Should hyperlipidaemia in dialysis patients be treated?. NEPHROLOGY DIALYSIS TRANSPLANTATION, 12 (1), 19-21. doi:10.1093/ndt/12.1.19
Chana, R.S., Milford, D.V., Pawluczyk, I.Z.A., Wheeler, D.C. (1997). Tacrolimus inhibits cytokine-mediated fibronectin production by mesangial cells..

1996

Rajman, I., Kendall, M.J., Wheeler, D.C. (1996). Abnormal LDL subfraction profiles in renal transplant recipients..
Wheeler, D.C. (1996). Abnormalities of lipoprotein metabolism in CAPD patients.. KIDNEY INTERNATIONAL, 50 S41-S46.
Wheeler, D.C. (1996). Cardiovascular disease in patients with chronic renal failure.. LANCET, 348 (9043), 1673-1674. doi:10.1016/S0140-6736(05)65816-3
Chana, R.S., Wheeler, D.C. (1996). Effects of low density lipoprotein on mesangial cell adhesion molecule expression..
Goldstein, D.J., Wheeler, D.C., Salant, D.J. (1996). Effects of omega-3 fatty acids on complement-mediated glomerular epithelial cell injury.. KIDNEY INTERNATIONAL, 50 (6), 1863-1871. doi:10.1038/ki.1996.507
Wheeler, D.C., Morgan, R., Thomas, D.M., Seed, M., Rees, A., Moore, R.H. (1996). Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients.. TRANSPLANT INTERNATIONAL, 9 (3), 221-226. doi:10.1007/BF00335389
Sheridan, A.M., Fitzpatrick, S., Wang, C., Wheeler, D.C., Lieberthal, W. (1996). Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells.. KIDNEY INTERNATIONAL, 49 (1), 88-93. doi:10.1038/ki.1996.12

1995

RAJMAN, I., HARPER, L., KENDALL, M.J., WHEELER, D.C. (1995). ATHEROGENIC LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTION PROFILES IN DIALYSIS PATIENTS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 6 (3), 558.
Goldstein, D.J., Wheeler, D.C., Sandstrom, D.J., Kawachi, H., Salant, D.J. (1995). Fish oil ameliorates renal injury and hyperlipidemia in the Milan normotensive rat model of focal glomerulosclerosis.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 6 (5), 1468-1475.
Wheeler, D.C. (1995). Lipids--what is the evidence for their role in progressive renal disease?. NEPHROLOGY DIALYSIS TRANSPLANTATION, 10 (1), 14-16.
WHEELER, D.C., CHANA, R.S., THOMAS, G.J., WILLIAMS, J.D., DAVIES, M. (1995). LOW-DENSITY-LIPOPROTEIN STIMULATES MESANGIAL CELL PROTEOGLYCAN PRODUCTION. KIDNEY INTERNATIONAL, 47 (2), 690-691.

1994

Harper, G.D., Wheeler, D.C., Wicks, A.C. (1994). Butterfat absorption--a valuable screening test in malabsorption.. POSTGRADUATE MEDICAL JOURNAL, 70 (819), 23-26. doi:10.1136/pgmj.70.819.23
WHEELER, D.C., MORGAN, R., REES, A., MOORE, R.H. (1994). FACTORS DETERMINING LIPID AND APOPROTEIN LEVELS IN RENAL-TRANSPLANT RECIPIENTS.
Wheeler, D.C., Bernard, D.B. (1994). Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment.. AMERICAN JOURNAL OF KIDNEY DISEASES, 23 (3), 331-346. doi:10.1016/S0272-6386(12)80994-2
Banerji, C., Wheeler, D.C., Morgan, J.R. (1994). Listeria monocytogenes CAPD peritonitis: failure of vancomycin therapy.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 33 (2), 374-375. doi:10.1093/jac/33.2.374
WHEELER, D.C., CHANA, R.S., THOMAS, G.J., STEADMAN, R., DAVIES, M., WILLIAMS, J.D. (1994). LOW-DENSITY-LIPOPROTEIN STIMULATES PRODUCTION OF HYALURONIC-ACID BY HUMAN MESANGIAL CELLS IN-VITRO. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 5 (3), 823.
Wheeler, D.C., Chana, R.S., Topley, N., Petersen, M.M., Davies, M., Williams, J.D. (1994). Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury.. KIDNEY INTERNATIONAL, 45 (6), 1628-1636. doi:10.1038/ki.1994.214

1993

LIEBERTHAL, W., KROSHIAN, V.M., WHEELER, D.C., SHERIDAN, A.M. (1993). CULTURED RENAL EPITHELIAL-CELLS ARE DEFICIENT IN ESSENTIAL FATTY-ACIDS. FASEB JOURNAL, 7 (3), A146.
WHEELER, D.C., GOLDSTEIN, D.J., SALANT, D.J. (1993). FATTY-ACID SUBSTITUTION MODIFIES COMPLEMENT-STIMULATED THROMBOXANE-B(2) PRODUCTION BY GLOMERULAR EPITHELIAL-CELLS. FASEB JOURNAL, 7 (3), A44.
Wheeler, D.C., Chana, R.S. (1993). Interactions between lipoproteins, glomerular cells and matrix.. MINERAL AND ELECTROLYTE METABOLISM, 19 (3), 149-164.
Thomas, M.E., Harris, K.P., Ramaswamy, C., Hattersley, J.M., Wheeler, D.C., Varghese, Z., ...Moorhead, J.F. (1993). Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.. KIDNEY INTERNATIONAL, 44 (5), 1124-1129. doi:10.1038/ki.1993.358

1992

WHEELER, D.C., CHANA, R.S., TOPLEY, N., DAVIES, M., WILLIAMS, J.D. (1992). EFFECTS OF NATIVE AND OXIDIZED LOW-DENSITY-LIPOPROTEIN (LDL) PARTICLES ON HUMAN MESANGIAL CELL-GROWTH AND VIABILITY INVITRO. KIDNEY INTERNATIONAL, 41 (3), 699.
Wheeler, D.C. (1992). Lipid abnormalities in renal disease. In AEG, R. (Ed.), Advanced renal medicine. (pp. 54-68). Oxford, UK: Oxford University Press.
Thomas, D.M., Moore, R., Donovan, K., Wheeler, D.C., Esnault, V.L., Lockwood, C.M. (1992). Pulmonary-renal syndrome in association with anti-GBM and IgM ANCA.. LANCET, 339 (8804), 1304. doi:10.1016/0140-6736(92)91640-T

1991

Wheeler, D.C., Fernando, R.L., Gillett, M.P., Zaruba, J., Persaud, J., Kingstone, D., ...Moorhead, J.F. (1991). Characterisation of the binding of low-density lipoproteins to cultured rat mesangial cells.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 6 (10), 701-708. doi:10.1093/ndt/6.10.701
Wheeler, D.C., Nair, D.R., Persaud, J.W., Jeremy, J.Y., Chappell, M.E., Varghese, Z., Moorhead, J.F. (1991). Effects of dietary fatty acids in an animal model of focal glomerulosclerosis.. KIDNEY INTERNATIONAL, 39 (5), 930-937. doi:10.1038/ki.1991.116
Donovan, K.L., Thomas, D.M., Wheeler, D.C., Macdougall, I.C., Williams, J.D. (1991). Experience with a new method for percutaneous renal biopsy.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 6 (10), 731-733. doi:10.1093/ndt/6.10.731

1990

WHEELER, D.C., NAIR, D.R., PERSUAD, J.W., VARGHESE, Z., MOORHEAD, J.F. (1990). DIETARY FATTY-ACID INTAKE INFLUENCES PROGRESSION OF GLOMERULOSCLEROSIS IN THE OBESE ZUCKER RAT. KIDNEY INTERNATIONAL, 37 (1), 524.
Wheeler, D.C., Persaud, J.W., Fernando, R., Sweny, P., Varghese, Z., Moorhead, J.F. (1990). Effects of low-density lipoproteins on mesangial cell growth and viability in vitro.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 5 (3), 185-191. doi:10.1093/ndt/5.3.185

1989

Sweny, P., Wheeler, D.C., Lui, S.F., Amin, N.S., Barradas, M.A., Jeremy, J.Y., ...Moorhead, J.F. (1989). Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection.. Nephrology Dialysis Transplantation, 4 (12), 1070-1075.
Moorhead, J.F., Wheeler, D.C., Varghese, Z. (1989). Glomerular structures and lipids in progressive renal disease.. The American journal of medicine, 87 (5N), 12N-20N.
Wheeler, D.C., Varghese, Z., Moorhead, J.F. (1989). Hyperlipidemia in nephrotic syndrome.. AMERICAN JOURNAL OF NEPHROLOGY, 9 78-84. doi:10.1159/000168044
MOORHEAD, J.F., WHEELER, D.C., FERNANDO, R., SWENY, P., VARGHESE, Z. (1989). INJURY TO RAT MESANGIAL CELLS IN CULTURE BY LOW-DENSITY LIPOPROTEINS. KIDNEY INTERNATIONAL, 35 (1), 433.
WHEELER, D.C., PERSAUD, J., KINGSTONE, D., SWENY, P., VARGHESE, Z., MOORHEAD, J.F. (1989). RECEPTOR MEDIATED BINDING OF HUMAN LOW-DENSITY LIPOPROTEIN (LDL) TO RAT MESANGIAL CELLS-INVITRO. KIDNEY INTERNATIONAL, 35 (1), 439.

1988

Wheeler, D.C. (1988). Hyperlipidaemia and atherosclerosis complicating renal disease. In Sweny, P., Farrington, K., Moorhead, J.F. (Eds.), The kidney and its disorders. (pp. 522-537). London, UK: Blackwell.
Wheeler, D.C., Sweny, P., Varghese, Z., Moorhead, J.F. (1988). Hyperlipidaemia and atherosclerosis in chronic dialysis patients. In Maher, J.F. (Ed.), Replacement of renal function by dialysis. (pp. 798-807). Dordrecht, Netherlands: Martinus Nijhoff.
WHEELER, D.C., LUI, S.F., VARGHESE, Z., KINGSTONE, D., PERSAUD, J., SWENY, P., ...MOORHEAD, J.F. (1988). OMEGA-3 POLY-UNSATURATED FATTY-ACIDS (PUFAS) IMPROVE LIPID PROFILE BUT NOT RENAL HEMODYNAMICS IN RENAL-TRANSPLANT RECIPIENTS (RTR). KIDNEY INTERNATIONAL, 33 (1), 456.

1987

Feehally, J., Wheeler, D.C., Walls, J., Jones, S., Lockwood, C.M., Savage, C.O. (1987). A case of microscopic polyarteritis associated with antineutrophil cytoplasmic antibodies.. CLINICAL NEPHROLOGY, 27 (4), 214-215.
WHEELER, D.C., SMITH, B.A., WALLS, J., BEAMAN, M. (1987). MAGNESIUM-HYDROXIDE AS A PHOSPHATE BINDER IN CAPD PATIENTS WITH ELEVATED SERUM ALUMINUM LEVELS. PERITONEAL DIALYSIS BULLETIN, 7 (1), 44-45.
Wheeler, D.C., Cosgriff, P.S., Bennett, S.E., Walls, J. (1987). Measurement of renal functional reserve of the single kidney in man.. CLINICAL NEPHROLOGY, 28 (2), 87-92.
Feehally, J., Wheeler, D.C., Mackay, E.H., Oldham, R., Walls, J. (1987). Recurrent acute renal failure with interstitial nephritis due to D-penicillamine.. RENAL FAILURE, 10 (1), 55-57. doi:10.3109/08860228709047645

1986

Wheeler, D.C., Feehally, J., Walls, J. (1986). High risk acute renal failure.. QUARTERLY JOURNAL OF MEDICINE, 61 (234), 977-984.
Wheeler, D.C., Smith, B., Walls, J. (1986). Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.. LANCET, 1 (8494), 1380.
WHEELER, D.C., FEEHALLY, J., BURTON, P., WALLS, J. (1986). THE KIDNEY IN MYELOMA. BRITISH MEDICAL JOURNAL, 292 (6516), 339. doi:10.1136/bmj.292.6516.339-c

1985

Wheeler, D.C., Calvey, H.D., Wicks, A.C. (1985). A difficult pain in the neck.. BRITISH MEDICAL JOURNAL, 291 (6498), 804-805. doi:10.1136/bmj.291.6498.804
Wheeler, D.C., Ayres, J.G., Skinner, C. (1985). Carbimazole-induced jaundice.. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 78 (1), 75-76.

1984

WHEELER, D.C., WICKS, A.C.B. (1984). ATYPICAL POLYNEUROPATHY COMPLICATING RECTAL-CARCINOMA. BRITISH MEDICAL JOURNAL, 289 (6456), 1424.
Ayres, J., Fish, D.R., Wheeler, D.C., Wiggins, J., Cochrane, G.M., Skinner, C. (1984). Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping.. BRITISH MEDICAL JOURNAL, 288 (6432), 1715-1716. doi:10.1136/bmj.288.6432.1715

1982

Vale, J.A., Wheeler, D.C. (1982). Anaphylactoid reaction to acetylcysteine.. LANCET, 2 (8305), 988.

1900

D'Aiuto, F., Koukos, G., Suvan, J., Wheeler, D.C., Donos, N. (1900). Association of Oral Health with Chronic Kidney Disease.